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CHAPTER I 
 
INTRODUCTION 
 
Breast cancer 
One in three American women is predicted to develop breast cancer in the course of her 
lifetime 1, 2.  Patients suffering from breast cancer do not usually die from the growth of 
the tumor at the primary site but rather from the spreading of the cancer cells to distant 
organs 3, 4.  A study on more than 500 patients presenting with advanced breast cancer 
showed that 69 % of these women had evidence of bone metastases 5.  Bone metastasis 
causes severe complications such as pain, pathological fractures, nerve compression 
syndromes and hypercalcemia which greatly affect the quality of life of the patients 6.  
Furthermore, once breast to bone metastases are actively growing, only palliative 
treatments can be offered to the patient as no cure is currently available.   
 
Physiology of the bone 
The fact that breast cancer displays significant osteotropism was first observed by 
Stephen Paget in 1889 when he noted that “in cancer of the breast the bones suffer in a 
special way, which cannot be explained by any theory of embolism alone” 7.  Why do 
breast cancer tumor cells have such a significant affinity to the skeleton? What makes the 
bone such a preferential environment for breast tumor cells?  Despite the increasing 
numbers of studies conducted, our knowledge on the molecular mechanisms underlying 
breast to bone metastasis remains limited.  Since metastatic tumor cells hijack the normal 
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bone remodeling process to their own benefit, we will first explore the normal 
physiological bone turn-over process. 
 
Normal bone constituents 
The skeleton has two main functions; 1) to support and to protect all vital organs and 
bone marrow and to be an anchoring point for muscles allowing for locomotion and 2) to 
serve as a reservoir for calcium, phosphates, hematopoietic progenitor cells and growth 
factors such as transforming growth factor-β (TGF-β) or insulin growth factors (IGFs) 8.  
Two types of bone are found in the normal skeleton: cortical and trabecular bone (Figure 
1).  Although macroscopically and microscopically different, these two types of bone 
present the same chemical composition.  Cortical bone is dense, compact, mainly 
calcified and represents 80% of the skeleton; its main function is to support the body 
weight and to provide protection of all the internal organs 8.  Although representing only 
20% of the body mass, trabecular bone is 80% of the bone surface inside the long bones, 
the vertebrae, the pelvis and the large flat bones 8.  Trabecular bone is less dense, presents 
a higher turn-over rate than the cortical bone and exhibits mainly a metabolic function. 
The bone matrix is primarily composed of type I collagen and non-collagenous proteins 
such as osteocalcin, bone sialoprotein and osteopontin (OPN).  Crystals of calcium 
compounds (hydroxyapatite crystals) are also found on and within the collagen fibers as 
well as in the matrix and these crystal structures give strength to the bone matrix 9.  
Osteoblasts are the cells responsible for the production of the bone constituents 
and are derived from the mesenchymal stem cells which can also give rise to fibroblasts, 
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chondrocytes, myoblasts and adipocytes 10 (Figure 1).  Osteoblasts are typically found in 
clusters lining the bone matrix being formed.  Bone formation occurs in multiple steps 1) 
the synthesis of the extracellular matrix (ECM) or osteoid, 2) the maturation of the 
osteoid and 3) the mineralization of the osteoid.  Osteoblasts are also responsible for the 
production and deposition of growth factors in the osteoid matrix such as TGF-β, IGFs, 
platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and bone 
morphogenetic proteins (BMPs) 11.  Therefore, bone serves as a reservoir of growth 
factors, readily accessible via osteolysis when needed.  Furthermore, these growth factors 
can regulate the activity of osteoblasts upon their release from the bone matrix, providing 
a feedback loop that ensures the proper coupling between bone formation and resorption.  
During osteoid synthesis a small subset of osteoblasts are entrapped in the newly forming 
bone and undergo terminal differentiation into osteocytes 12.  
Osteocytes form a highly complex canicular network in the bone (Figure 1). The 
canicules contain osteocytic processes enabling the osteocytes to sense any alteration in 
the integrity of the bone as well as making contact with the osteoblasts and osteoclasts 
lining the bone surface13, 14.  It has been proposed that microfractures and microcracks in 
the bone are detected by osteocytes which in turn induce the activation of the bone 
remodeling process 15.  Furthermore, osteocytes can suppress bone formation by secreting 
factors such as sclerostin 16.   
Osteoclasts are the third major cell constituents of the bone and are responsible 
for osteolysis (Figure 1).  They are derived from myeloid stem cells which give rise to 
monocytes, macrophages and dendritic cells 17.  Mature osteoclasts are giant 
3 
 
 Figure 1.  Histology of mouse tibia. 
Representative hematoxylin and eosin photomicrograph of a wild type mouse tibia (50X, 
scale bar is 50µm).  Higher magnification images show the three main bone cell types :
osteoblasts, osteocytes and osteoclasts. Scale bar is 50µm. 
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multinucleated cells resulting from the fusion of activated monocytes 18.  Lining the 
surface of the bone, mature osteoclasts adhere to the bone matrix via integrins such as 
αVβ3 which induce the reorganization of their cytoskeleton to form a sealing zone 
isolating the extracellular compartment from the bone resorption process 17.  Underneath 
the sealing zone, osteoclasts induce acidification of the resorption lacunae via an 
electrogenic proton pump (H+-ATPase) and a Cl- channel 19.  The acidification of the 
milieu allows the mobilization of the mineralized components of the bone matrix, 
exposing the type I collagen which is degraded by acidophilic collagenases secreted by 
osteoclasts, the main protease being cathepsin K 17.  Osteoclast functions are regulated by 
a number of cytokines such as receptor activator of NF-ĸB ligand (RANKL), interleukin-
1 (IL-1), tumor necrosis factor-α (TNF-α), macrophage colony-stimulating factor (M-
CSF), growth factors (IGF-I, PDGF) and hormones (parathyroid hormone (PTH), insulin) 
10. 
 
Normal bone remodeling process 
Bone remodeling is a complex process by which old bone is replaced by new tissue.  
Osteoblast communication with osteoclasts is crucial for this process (Figure 2).  There 
are several mechanisms that facilitate osteoblast-osteoclast communication. 1) Direct 
contact through membrane-bound ligand-receptor interactions, allows the activation of 
intracellular pathways in both osteoblasts and osteoclasts.  2) Osteoblasts and osteoclasts 
can form gap junctions enabling the diffusion of small water-molecules.  3) Paracrine 
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 Figure 2. Normal bone remodeling process. 
Osteoblasts are responsible for the deposition of the new bone matrix and the secretion of
growth factors such as TGF-β and IGFs stored in the newly forming bone. Osteocytes are
terminally differentiated osteoblasts, entrapped in the newly formed bone and act as its 
sentinel. (1) Osteoblasts express at their cell surface RANKL, a key factor in the bone
remodeling process, which binds to its receptor present at the membrane of osteoclasts
precursor cells. (2) RANKL interaction with its receptor induces the 
activation/maturation of osteoclast precursors into multinucleated mature osteoclasts
which are the cells responsible for bone resorption. (3) Osteoclast-mediated osteolysis 
induces the release of growth factors like TGF-β and IGFs stored in the bone which are 
able to signal back to the osteoblasts and osteoclasts and therefore act as a feedback loop 
to control the extent of the normal bone resorption taking place. 
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factors such as growth factors, cytokines and chemokines can be secreted by one cell type 
and act on the other through diffusion. For example, Allan and colleagues demonstrated 
that PTH and PTH-related peptide (PTHrP) can regulate the level of expression of 
ephrinB2 in osteoblasts, and that the blockage of the interaction of ephrinB2 with its 
receptor EphB4 expressed by osteoclasts inhibits osteoblast function 20, 21.  Furthermore, 
ephrinB2/EphB4 binding inhibits osteoclast differentiation 22.  Local factors such as IL-
11, prostaglandin E2, onconstatin M, PTHrP and microdamage sensed by osteocytes 
induce the expression of RANKL by osteoblasts.  RANKL is a member of the TNF 
family and a key factor in bone remodeling. It has been well established that the 
interaction of RANKL with its receptor RANK expressed by myeloid osteoclast 
precursors is essential for osteoclastogenesis 23.  Osteoblasts also expressed 
osteoprotegerin (OPG), which acts as a decoy receptor for RANKL, thus regulating bone 
resorption by competing for RANK-binding at the surface of osteoclasts 24.  In addition to 
RANKL, oteoblasts secrete macrophage colony-stimulating factor (M-CSF) which is 
required for monocytic/macrophage precursor cell survival 25.  RANKL/RANK 
interaction induces the fusion of osteoclast precursor cells leading to the formation of 
multinucleated mature osteoclasts 26.  It has been well established that the cysteine 
proteinase cathepsin K is the principal enzyme responsible for the degradation of the 
demineralized bone matrix 27.  Mice deficient for cathepsin K showed an accumulation of 
demineralized collagen fibers in the subosteoclastic resorption lacunae demonstrating the 
predominant role of this enzyme in bone degradation 28.  Cathepsin K cleaves type I 
collagen releasing the triple helix which becomes more susceptible to proteolytic 
degradation by other collagenases 29.  In addition to cathepsin K, studies conducted by 
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Everts and colleagues demonstrated that treatment of calvarias with matrix 
metalloproteinase (MMP) inhibitors (MMPIs) leads to a significant amount of 
demineralized bone matrix accumulating in the resorption lacunae, demonstrating the 
importance of MMPs in regulating bone resorption 30-32.  However, whether these effects 
are due to direct or indirect activity of MMPs remains unknown. 
 
Matrix Metalloproteinases 
 
Classification and structure 
The metzincin superfamily of proteolytic enzymes is characterized by a conserved zinc 
binding motif HEXXHXXGXXHZ where the histidine (H), glutamic acid  (E) and 
glycine (G) are invariant and the 3 histidines are responsible for the binding of the 
catalytic Zn2+ ion 33.  Of this superfamily of proteases, MMPs form a subfamily of 23 
human endopeptidases where the Z residue is a serine in the zinc motif in all but few 
MMP family members.  In addition to the zinc motif, MMPs share some sequence 
homologies, conferring to this family a conserved overall structure.  Thus, they are often 
classified according to their domain structure into several groups including the 
collagenases, the gelatinases, the stromelysins and the membrane-type MMPs (MT-
MMPs) (Figure 3) 34.   
The minimal modular domain structure common for all the MMPs consists of a 
pre domain (for secretion), a pro domain (for latency maintenance) and a catalytic  
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Figure 3. Domain structures of the MMP family. 
Pre: pre doman; Pro: pro domain; CAT: catalytic domain; hemopexin: hemopexin 
domain; FN: fibronectin domain; ~ : hinge region; O: O-glycosylated domain; F: furin 
cleavage site; TM: transmebrane domaine Type I; GPI: GPI anchor; C Array: cysteine 
array’; Ig like: Ig-like domain.  
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domain (for proteolytic activity) 35.  All the MMPs are produced as pro-enzymes or 
zymogens where their latency is ensured by the bond of the cysteine in the pro domain 
with the Zinc2+ ion of the catalytic region.  Activation of pro/latent MMPs has been 
described as a ‘cysteine switch’.   Cleavage of the pro domain alters this cysteine/Zinc2+ 
interaction and the zinc ion becomes susceptible to hydrophilic attack, allowing for the 
subsequent interaction of a substrate with the catalytic domain 36.  Most of the MMPs, 
except MMP-7, MMP-23 and MMP-26, have a hemopexin/vitronectin domain linked to 
the catalytic domain by a hinge region.  This hemopexin domain influences the binding 
of tissue inhibitors of metalloproteinases (TIMPs), substrate binding, membrane 
localization and proteolytic activity 37.  MMP-2 and MMP-9 also contain a fibronectin 
type II repeat within the catalytic domain required for the binding and cleavage of 
collagen and elastin 38, 39.  Finally, MT-MMPs can be divided in 2 categories: the type I 
transmembrane MMPs (MMP-14, -15, -16 and -24) presenting a short cytoplasmic C-
terminal tail, and the glycophosphatidyl inositol (GPI) MT-MMPs (MMP-17 and -25) 
possessing a C-terminal hydrophobic tail 34.  These different domains play a crucial role 
for the localization and the regulation of the activity of the different MMP family 
members.  
 
Regulation of MMPs 
The specific biological function of individual MMPs is mainly dictated by their temporal, 
spatial and inducible pattern of expression.  MMP expression and activation are highly 
regulated at the transcriptional and post-translational levels 40.  MMP gene expression is 
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controlled by various growth factors and cytokines (TGF-β, epithelial growth factor/EGF, 
TNF-α), integrin-derived signals, ECM proteins, phorbol esters, cell stress and changes in 
cell shape 41.  The majority of these stimuli induce the expression or activation of proto-
oncogenes such as c-fos and c-jun, as well as β-catenin and ets transcription factors that 
mediate the transcription of specific MMPs 37.   
 MMPs are secreted as pro-enzymes or zymogens and their activation is tightly 
regulated.  MMP-11, MMP-23 and MT-MMPs contain a furin-like enzyme recognition 
domain between the pro and catalytic domains and can be activated by subtilisin-type 
serine proteinases such as furin in the intracellular compartment 42.  All other MMPs are 
activated outside of the cell by either already activated MMPs or by other proteinases 43.  
MMP-2 presents an additional unique serine-independent mode of activation involving 
MT1-MMP and TIMP-2 40.  TIMP-2 is anchored at the cell surface through the binding 
of its N-terminal domain to MT1-MMP and acts as a receptor for MMP-2 via the binding 
of its C-terminal domain to MMP-2 hemopexin domain.  Subsequently, a neighboring 
active MT1-MMP can cleave and activate the anchored proMMP-2 when low levels of 
TIMP-2 are present 44.   
 Once activated, MMP activity can be closely regulated by endogenous inhibitors 
such as α2-macroglobulin and TIMPs 45.  α2-macroglobulin is an abundant plasma 
protein and acts mainly as a major protease and MMP inhibitor in plasma 46.  TIMPs 
represent a family of 4 secreted proteins expressed mainly in various tissues and fluids.  
They reversibly inhibit MMP activity in a 1:1 stoichiometric ratio through the 
interactions of their N-terminal domain with the MMP catalytic site 47.  However, besides 
their ability to inhibit MMP activity, studies have demonstrated MMP-independent 
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functions of TIMPs.  For example, TIMP-1, -2 and -3 have been shown to promote cell 
growth 48. Furthermore, TIMP-1 and TIMP-2 have been demonstrated to inhibit tumor 
angiogenesis in an MMP-independent fashion 49, 50.MMP substrates in the bone 
The classical substrates for MMPs are the various proteins, proteoglycans and 
glycoproteins constituting the ECM (Table 1).  In addition, through the processing of 
signaling molecules such as growth factors, cell surface proteins and cytokines, MMPs 
contribute to numerous cell functions (Table 1).  Thus, MMPs because of their wide array 
of substrates are involved in a number of biological processes such as mammary gland 
involution, angiogenesis and modulation of immune reactions 33. 
Since bone is composed of over 90% type I collagen, enzymes with collagenase 
activity are predicted to be important proteases in bone remodeling.  Delaisse and 
colleagues demonstrated that levels of collagenases positively correlate with elevated 
rates of bone resorption in calvarias 51.  Several lines of evidence have suggested that 
osteoblast-derived collagenases may play a role in bone resorption initiation as bone 
resorbing agents induce collagenase expression by osteoblasts52, 53.  Furthermore, in vivo 
osteoblasts adjacent to activated osteoclasts present high levels of collagenase 54, 55.  It 
has been proposed that collagenases degrade the non-mineralized organic matrix allowing 
osteoclast precursors to adhere to the mineralized bone and become activated 56.  
Furthermore, collagenases may release molecules or collagen fragments that can 
stimulate osteoclast activation 57, 58.  In transgenic mice expressing a type I collagen 
resistant to MMP-dependent collagenase degradation, calvaria lack a bone marrow cavity 
and are significantly thicker than in the wild type control mice 59.  These studies suggest 
the importance of collagenases in bone resorption, and that cathepsin K and MMPs may  
12 
 
MMP ECM substrates Non-matrix substrates
MMP-1 
Collagen I, II, III, VII, X, XI; gelatin, 
entactin; aggrecan; fibronectin; 
laminin; tenascin; vitronectin
Perlecan; IGFBP-2, IGFBP-3; pro-TNF-α; 
α1-AC; α2-MG; α1-PI 
MMP-2 
Collagen I, III, IV, V, VII, X, XI; 
gelatin; elastin; fibronectin; laminin; 
aggrecan; tenascin; decorin; 
vitronectin 
LAP-TGF-β, LTBP-1, TGF-β2; IL-1β; 
MCP-3; SDF-1; IGFBP-3; IGFBP-5; 
TNF-α; FGFR-1; α1-PI 
MMP-3 
Collagen III, IV, V, VII,IX,  X, XI; 
gelatin; elastin; fibronectin; laminin; 
aggrecan; tenascin; decorin; 
vitronectin; entactin
Perlecan; IGFBP-3; TNF-α; α1-AC; α2-
Mg; α1-PI; HB-EGF; IL-1β; plasminogen; 
E-cadherin;  
MMP-7 
Collagen I, IV; gelatin; elastin; 
fibronectin; laminin; aggrecan; 
tenascin; decorin; vitronectin; entactin
TNF-α; FasL; α1-PI; HB-EGF; 
plasminogen; E-cadherin; β4 integrin 
MMP-8 Collagen I, II, III; aggrecan Α2-MG; α1-PI 
MMP-9 Collagen IV,  X, XIV; gelatin; elastin; laminin; aggrecan; decorin; vitronectin 
LAP-TGF-β, TGF-β2; IL-1β;; SDF-1; 
TNF-α; FGFR-1; α1-PI; IL-2Ra; α2-MG 
MMP-10 Collagen III, IV, V; gelatin; elastin; aggrecan; fibronectin Not known 
MMp-11 Not known IGFBP-1; α1-PI; α2-MG
MMP-12 Collagen I, IV; gelatin; elastin; laminin; entactin Plasminogen; α1-PI; α2-MG 
MMP-13 Collagen I, II, III, IV, IX, X, XIV; gelatin; fibronectin; aggrecan α2-MG 
MMP-14 
Collagen I, II, III; gelatin; laminin; 
aggrecan; fibronectin; vitronectin; 
entactin
CD44; transglutaminase; α1-PI; α2-MG 
MMP-16 Collagen III; fibronectin; gelatin transglutaminase 
MMP-17 Gelatin TNF-α; α2-MG 
MMP-18 (Xenopus) Collagen I Not known 
MMP-19 
Collagen I, IV; gelatin; laminin; 
aggrecan; fibronectin; tenascin; 
entactin; COMP 
 
MMP-20 Collagen XVIII; aggrecan; amelogenin; COMP Not known 
MMP-21 (Xenopus) Not known Not known 
MMP-22 (chicken) Gelatin Not known 
MMP-23 Not known Not known 
MMP-24 Collagen I; geltin; laminin; fibronectin Not known 
MMP-25 Collagen IV; gelatin; fibonectin Not known 
MMP-26 Collagen IV; gelatin; fibronectin α1-PI 
MMP-27 Not known Not known 
MMP-28 Not known Not known 
 
 
Table 1. Matrix and non-matrix substrates of MMPs.  (Lynch and Matrisian, 2002) 
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have different roles in intramembranous and endochondral bone.   Cathepsin K cleavage 
of the native triple helix of collagen releases C-terminal (CTX) and N-terminal (NTX) 
cross-linked telopeptides which have been shown to be good serum markers for 
osteoporosis 60.  MMPs such as MMP-1, -2, -8, -9, -13 and MT1-MMP have collagenase 
activity in vitro 61.  But in contrast to cathepsin K, MMPs generate a larger cross-linked 
C-terminal telopeptide of type I collagen (ICTP).  The ICTP fragment has been shown to 
significantly correlate with extent of bone lesions in patients presenting bone metastasis 
and to act as chemotactic molecules for osteoclast precursor cells 62-64.  Cleavage of type I 
collagen also leads to the exposure of cell adhesion sites such as binding sites for 
integrins, especially αVβ3 integrin, influencing the attachment/detachment of osteoclasts 
and ultimately regulating their migration during bone resorption 65.  MMP-3 and -7 have 
also been shown to process non-collagenous components of the bone matrix such as 
OPN, resulting in the exposure of integrin binding sites which could regulate cell 
adhesion to the bone matrix 66. 
In addition to processing bone matrix components, MMPs have also been shown 
to process numerous non-matrix substrates, several of which are pertinent to the bone 
(Table 2).  Therefore, MMPs can regulate cell behavior by altering the activity status of 
numerous growth factors and cytokines. For that reason, roles for MMPs, independent of 
their ability to degrade the ECM, are a distinct possibility in the bone microenvironment.  
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Roles of MMPs in normal bone physiology 
To date, roles for only a small number of MMPs have been described in bone based on 
MMP deficient animals.   
Itoh and colleagues first described MMP-2 deficient mice and reported that these 
mice have a significantly slower growth rate compared to wild type mice 67.  More 
detailed studies have shown that MMP-2 deficient mice also have abnormal cranio-facial 
defects mirroring those of the nodulis, arthropathy and osteolysis (NAO) syndrome in 
humans having a mutation in mmp2 gene 68, 69.  MMP-2 deficient mice also demonstrate 
severe osteoporosis and a significant thickening of the calvaria by 55 weeks of age 
compared to wild type control mice 68.  Inoue and colleagues also reported the expression 
of MMP-2 by osteoblasts and osteocytes.  Calvaria of MMP-2 deficient mice showed a 
defect in osteocytic canicular network suggesting a contribution of MMP-2 in the 
maintenance of the canicular network which is important for the development of the 
skeleton 68.  In addition, studies have shown that MMP-2 mediates osteoblast 
proliferation and differentiation 69. 
MMP-7 deficient mice have no obvious skeletal defects 70.  However, the 
phenotype of MMP-7 deficient animals becomes apparent during physiological stresses 
such as disease or injury for example, MMP-7 has been reported to be important for joint 
destruction in the development of septic arthritis 71.  Haro and coworkers also 
demonstrated that macrophage-derived MMP-7 was required for the release of TNF-α by 
macrophages in a model of herniated disc resorption 72.   
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 In the bone environment, MMP-9 has been reported to be largely expressed by 
multinucleated osteoclasts 73.  However, MMP-9 deficient mice do not present any 
obvious skeletal defect.  Despite no overt phenotype, Vu and colleagues reported a 
transient phenotype in the hypertrophic zones of long bones 74.  This is primarily due to a 
delay in vascularization and apoptosis of chondrocytes inducing a lengthening of the 
growth plate caused by a defect of osteoclast and endothelial cell invasion into the 
mineralized cartilage 74, 75.  In absence of MMP-9, vascular endothelial growth factor 
(VEGF) was found to be sequestered in the ECM, which could explain the delay in 
angiogenesis and apoptosis of chondrocytes 76. 
 MMP-13 is the murine ortholog of human MMP-1 and is expressed by 
osteoblasts, osteocytes and mononuclear pre-osteoclast cells 77, 78.  Embryos deficient for 
MMP-13 present an elongated growth plate that is still evident at 3 months of age 79.  
Adult MMP-13 deficient mice show a thickening of the trabecular bone, potentially 
caused by an abnormal osteoblast proliferation and function rather than a defect in 
osteoclast activity 61. 
 Lastly, MT1-MMP is expressed in a number of bone cells but is particularly 
abundant in osteoclasts 80.  MT1-MMP deficient mice present a severe skeletal phenotype 
with delayed ossification of the calvaria and incomplete suture closure.  By 2 to 3 months 
after birth, most of the mice die 81-83.  Furthermore, homozygous mutant animals develop 
a generalized arthropathy with osteoclast-like giant cells in the articular tissues and a loss 
of osteocyte processes due to a defect in type I collagen degradation 81, 82.  Because of the 
role of MT1-MMP in MMP-2 activation, some of the skeletal defects observed in MT1-
MMP deficient mice could be caused by an absence of active MMP-2.  However, 
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Holmbeck and colleagues reported that impaired osteocyte processes observed in the long 
bones are associated with the loss of MT1-MMP 82.  MT1-MMP is importance for the 
maintenance of the osteocytic canicular network in tibias and femurs, but its contribution 
in osteocyte integrity in the calvaria remains to be determined 82.  Finally, degradation of 
the embryonic cartilage during skeletal development seems to be due to MT1-MMP 
collagenolytic activity 84. 
 
The ‘vicious cycle’ of bone metastasis 
Metastasis is a complex process where the tumor cells need to complete a cascade of 
events before reaching the bone.  Breast cancer cells have to break away from for primary 
tumor (1), invade the blood stream (2), survive in the blood circulation (3), adhere to 
vascular endothelium of a distant organ (4), extravasate from the blood vessel into the 
metastatic site (5) and finally proliferate in the secondary site (6) 85.  MMPs have been 
shown to play multiple roles in the progression of cancer 86.  Given the role of host 
MMPs in the bone development and physiology, it is clear that they may be relevant to 
tumor metastases to the bone and tumor-bone microenvironment 
After extravasation from the vasculature in the bone marrow cavity, metastatic 
tumor cells encounter a microenvironment that is metabolically active and rich in growth 
factors, cytokines and chemokines known to promote tumor growth.  Since bone is a hard 
tissue, breast tumor cells must hijack the normal bone resorption process in order to 
establish and grow (Figure 4).   Studies have demonstrated that metastatic breast tumor 
cells secrete various factors such as IL -1, -6, -8 and -11 and PTHrP that stimulate  
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Figure 4. The ‘vicious’ cycle of bone metastasis. (1) Metastatic tumor cells present in 
the bone, secrete various factors such as PTHrP and different interleukins which
stimulate (2) the osteoblasts to promote (3) the maturation and activation of osteoclast
precursors.  This high number of active osteoclasts leads (4) to an extensive bone
resorption, releasing increasing levels of growth factors such as TGF-β and IGFs.  (5) 
Besides promoting tumor growth in the bone, these growth factors have been shown (5) 
to modulate osteoblast and osteoclast functions that promote the continuation of the 
vicious cycle. 
osteoblast expression of osteoclastogenic factors M-CSF and RANKL 87.  It has been 
established for years that circulating PTH acts as a stimulus for bone remodeling, 
however PTHrP is a paracrine factor expressed mainly by osteoblast precursor cells and 
cells present in the bone marrow 88.  Both PTH and PTHrP have been shown to induce 
osteoblast differentiation and to inhibit osteoblast apoptosis 89.  Furthermore, mice 
heterozygous for PTHrP present a low level of bone formation and specific deletion of 
PTHrP expression in osteoblasts induced defective bone matrix synthesis 90, 91.  In 
addition to its effect on osteoblast differentiation and bone formation, PTHrP indirectly 
influences osteolysis by inducing osteoblast expression of RANKL, an important 
regulator of osteoclastogenesis 92.  PTHrP is expressed as a pre form which requires 
proteolytic cleavage to release the mature active peptide 93.  Furin and prostate serum 
antigen (PSA), two serine proteases, have been shown to cleave PTHrP inducing 
osteoblast differentiation 92, 94.  Immunohistochemical studies have demonstrated an 
increase of PTHrP expression in samples of breast cancer metastases to bone compared to 
soft tissues or primary breast tumor samples 95, 96.  Intracardiac injection of the human 
breast tumor cell line MDA-MB-231 overexpressing PTHrP increased the number of 
metastases in the bone 97.  Neutralizing antibodies to PTHrP injected in tumor bearing 
mice resulted in a decreased of both osteolytic lesions and tumor growth 97.  Taken 
together these data demonstrated that PTHrP expression is an important feature utilized 
by breast tumor cells to induce the vicious cycle of bone metastasis.   
 Bone is one of the richest reservoirs of growth factors such as TGF-β, IGFs and 
BMPs in the human body.  During bone synthesis, osteoblasts secrete these factors which 
become embedded in the new bone.  During the resorption of the bone, osteoclasts 
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release these growth factors that in turn provide signals to the osteoblasts to locally 
control the bone remodeling process.  IGFs are abundant growth factors sequestered in 
the bone matrix 98.  Supernatants of cultures of resorbing neonatal calvarias increased 
breast tumor proliferation 99.  A neutralizing antibody against IGF-I receptor significantly 
attenuated the growth effect of these calvarial culture supernatants suggesting that IGF 
released from the bone promotes tumor cell growth.   
In the bone, TGF-β possesses a unique role as it influences both bone resorption 
and bone formation.  TGF-β can influence chemotaxis, proliferation and maturation of 
osteoblast progenitor cells, and its effects appear to be both stimulatory and inhibitory 
depending on the differentiation state of the osteoblasts 100-104.  Osteoclast maturation and 
function are also influenced by TGF-β which has a dual stimulatory/inhibitory role 
depending on its levels 105-108.  These dual effects of TGF-β are essential for the fine 
regulation of bone remodeling, TGF-β levels act as a ‘sensor’ of the extent of bone 
resorption and formation either stimulating or inhibiting osteoclasts and osteoblasts to 
ensure locally controlled bone remodeling.  TGF-β has been shown to increase the 
expression and stabilize the mRNA of PTHrP in MDA-MB-231, contributing to the 
establishment and progression of breast tumor in the bone 97.  TGF-β is expressed by both 
differentiated osteoblasts and osteoclasts and released upon bone resorption; many 
studies have demonstrated its effect on normal and tumor cell proliferation, expression of 
matrix proteins and enzymes that control matrix turn-over such as MMPs 109-111.  Upon 
intracardiac injection, MDA-MB-231 cells expressing a dominant negative TGF-β 
receptor induced less osteoclast recruitment and thus induced less osteolysis.  Tumor 
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growth was also reduced which demonstrated the importance of TGF-β in promoting 
breast tumor progression in the bone 112.   
 
Potential contributions of MMPs to the ‘vicious cycle’ 
As reported in table 1, several non-matrix substrates including factors controlling the 
vicious cycle, are MMP substrates.  Through the release of active growth factors, MMPs 
could contribute in different steps of the vicious cycle 1) the growth of the tumor 2) 
osteolysis either by directly acting on osteoclast maturation and function or 3) indirectly 
by promoting osteoblast differentiation and expression of RANKL or 4) by inducing 
PTHrP expression by the tumor which can lead to osteoblast differentiation.  
PTHrP expression by metastatic tumor cells stimulate RANKL expression by 
osteoblasts and its subsequent interaction with RANK at the surface of osteoclast 
precursor cells result in osteoclast maturation and activation 33.  Although, no MMP has 
yet been shown to process PTHrP, a membrane bound metalloproteinase neprilysin 
(NEP) is able to modulate the activity of PTHrP 113-115.   
Lynch and colleagues reported that RANKL was processed by MMP-3 and 
MMP-7 116.  In an animal model of prostate tumor growth in the bone, they demonstrated 
that MMP-7 expression correlated with the level of tumor-induced osteolysis.  
Furthermore, they reported that MMP-7 was primarily expressed by mature osteoclasts 
present at the tumor-bone interface.  RANKL-processing mediated by MMP-7 resulted in 
a soluble form of RANKL which is as efficient and active as full length RANKL with 
respect to inducing osteoclast activation.  This finding was significant as it demonstrated 
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a novel way of activating osteoclast without the necessity of direct osteoblast-osteoclast 
contact 116.  This study demonstrated for the first time a direct contribution of a specific 
host MMP to the progression of the vicious cycle.  Besides MMP-3 and MMP-7, MMP-1 
and MMP-14 but also members of a disintegrin and metalloproteinase (ADAM) family 
such as ADAM-17 and ADAM-19 have been shown to generate soluble RANKL 117-119.   
TGF-β is maintained in a latent state through its the interaction with a latency 
associated peptide (LAP) and latent TGF-β binding proteins (LTBP-1-4) 120.  By 
processing the latent binding proteins that keep TGF-β in an inactive state, MMPs can 
enhance osteoclast function leading to a more extensive bone resorption 121-124.  This 
increased osteolysis can promote the release of higher levels of growth factors such as 
TGF-β itself and also IGFs which in turn could signal back to the osteoclast/osteoblast to 
induce more bone resorption and tumor growth.   
IGFs are expressed as a latent molecule through complexing with IGF binding 
proteins (IGFBP-1 to -4) 125.  The release of IGFs from IGFBPs has been shown to be 
mitogenic for various tumor cells such as breast, prostate and colon 126-128.  Furthermore, 
Wang and colleagues demonstrated that IGF-I is important for normal 
osteoclast/osteoblast interactions and can regulate osteoclastogenesis by promoting their 
differentiation 129.  Several MMPs have been shown to induce the release of IGFs via the 
processing of IGFBPs 130-133.  Therefore by contributing to the activation of IGFs, MMPs 
can affect osteoclast/osteoblast interactions and influence bone resorption. 
A number of other factors that can also be processed by MMPs exist in the tumor-
bone microenvironment (Table 2) and therefore, roles for the soluble factors generated by 
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other MMPs in vicious cycle are possible.  Given the potential contributions of MMPs to 
tumor progression in the tumor-bone microenvironment, through different matrix and 
non-matrix substrates, MMPs should be an attractive therapeutic target for the treatment 
of bone metastases. 
 
MMP inhibitors, still a viable treatment for tumor-induced bone lesions? 
By the virtue of their numerous substrates, MMPs have been implicated in every step of 
tumor progression from initiation to metastasis and as a consequence were thought to be   
ideal targets for drug therapies in the treatment of cancer 134.  However, human clinical 
trials using MMPIs largely failed to show efficacy due to the dose limiting side effects, 
mainly arthralgia, the broad spectrum of inhibition of the drugs used and the failure to 
identify appropriate end-point measures of the efficacy of the treatment 135.  Prolonged 
treatment with MMPIs, induced the development of musculoskeletal pain and 
inflammation and the question as of the identity of the MMPs responsible for these side 
effects arose 135.  Studies have demonstrated that broad spectrum inhibitors reducing 
‘sheddase’ activity of proteases do not seem to induce musculoskeletal side effects 136.  
Despite these side effects, MMPIs have been shown to be clinically efficient in the 
tumor-bone microenvironment.  Pre-clinical studies using broad spectrum MMPIs such 
as BB94 demonstrated that treatment of animal bearing breast or prostate tumor with 
MMPIs can reduce and prevent tumor growth and the development of bone lesions 137-139.   
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Table 2. Non-matrix substrates of MMP in the bone. 
 
Substrate Substrate Function MMP/References Product Function Role in bone microenvironment 
R
ec
ep
to
r 
FGFR
1 Receptor for FGF MMP-2
134, 135 
Soluble FGFR1 that 
inhibits FGF signaling by 
binding soluble FGF 
 Prevention of FGF effect on 
osteoblast differentiation 
and bone formation (BF) 
uPAR 
Regulates uPA activity 
at the cell surface and 
signaling. 
MMP-2, -3, -8, 9, 12, 
13, 14 136, 137 
Inactivation and deacrease 
in cell motility 
Inhibition of prostate cancer 
metastases to the bone by up 
to 80% 
LRP Endocytosis/Wnt signaling 
MMP-14, -15, -16, -
17138 
Inactivation of LRP 
attenuates endocytosis and 
Wnt signaling 
Inhibition of osteoblast 
differentiation and BF 
IL-
2Rα Interluekin receptor MMP-2, -9
139 
Inactivation and 
prevention of T-cell 
proliferation 
Generation of immune 
privileged site at the tumor 
bone interface 
FAS Fas ligand receptor MMP-7140 Inacivation of the receptor 
Prevention of FasL-
mediated osteoblast 
differentiation BF 
PAR-1 
G-protein coupled 
receptor activated by 
proteases 
MMP-1141 
Activation of the receptor 
and enhanced cell 
migration and invasion 
Activation of PAR-1 on 
tumor cells in the bone 
promotes migration. 
C
ty
ok
in
e/
G
ro
w
th
 F
ac
to
r 
HB-
EGF 
Pleiotropic effects on 
growth differentiation 
and apoptosis via ErbB-
4 and ErbB-1 
MMP-3, -7142-144 Active HB-EGF Myeloma progression 
IGF-
BPs 
Sequester IGF in a 
latent form 
MMP-1, -2, -3, -6,-
11130-133, 145 Active IGF 
Proliferation via activation 
of the IGF receptors 
FasL Induces apoptosis by activating Fas MMP-3, -7
146-149 Active soluble form of FasL 
Selection of apoptosis 
resistant tumor cells. 
Apoptosis of invading 
immune cells
TNF-α 
Pleiotropic effects on 
immune cells and 
tumor cells 
MMP-1, -2, -3, -7, -9, 
12, -14, -15, -17150-152 
Soluble active form of 
TNF-α 
Proximal and distal effects 
on cells. Activation of 
osteoclasts 
IL-1β 
Immunce cell activity 
and infiltration to sites 
of infection and tumor 
growth 
MMP-1, -2, -3, -9153-156 
Activation of the pro-form 
Inactivation of the mature 
cytokine 
Control of osteoclast 
maturation. Prevention of 
immune cell infiltration 
Kit 
Ligand 
Maintaining the stem 
cell niche in the bone MMP-9
157 Active soluble Kit ligand that can mobilize HPC’s 
Angiogenesis of the primary 
tumor and potential homing 
to the bone stem cell niche
C
el
l a
dh
es
io
n 
m
ol
ec
ul
es
 Cadhe
rins 
Cell :cell contact in 
epithelial, vascular and 
neuronal cells 
MMP-3, -7, -14158-161 
Degradation, leading to 
disassembly of the 
adherens junctions 
Greater tumor cell 
migration. Enhanced 
angiogenesis 
Integri
ns 
Cell contact with the 
basement membrane MMP-14
162, 163 
Maturation of the integrin 
and increased cell 
adhesion migration 
Migration of osteoclasts 
CD-44 Cell anchorage to the basement membrane 
MMP-14, 15, -16, 18, -
24164, 165 
Degradation of CD-44 
results in enhanced cell 
motility 
Increased tumor cells 
migration 
ICAM-
1 
Leukocyte infiltration 
and adhesion MMP-9
166 
Inactivation of ICAM-1 
leading to improper 
immune cell function 
Generation of immune 
privileged site at the tumor 
bone interface 
C
el
l s
ur
fa
ce
 g
ly
co
 
pr
ot
ei
ns
. 
EMM
PRIN 
Regulation of MMP 
activity and promtes 
cell migration? 
MMP-1, -2, 14, 15167-169 Soluble EMMPRIN can enhance MMP expression 
Potential induction of MMP 
expressio 
Mucin-
1 
Protection of epithelial 
cell surfaces MMP-14
170, 171 
Solubilization of Mucin-1 
influences tumor 
progression and invasion 
Expression of MUC-1 by 
tumor cells in the bone and 
processing by MMPs may 
allow for immunoevasion 
Sydeca
ns 
Cell adhesion to 
multiple ECM 
components 
MMP-7, -14, -16172-174 
Soluble syndecans can 
enhances tumor cell 
migration 
Expressed on tumor cells in 
the bone milieu and 
processing  by MMPs may 
promote migration  
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As a result, bone metastasis appears to be a relevant target for the use of MMPIs, 
however we need to identify the specific role of individual MMPs in the osteolytic tumor-
bone microenvironment 140.  The rationale for using more selective MMPIs in the tumor-
bone microenvironment has been shown by Bonfil and colleagues.  The authors 
demonstrated in a model of prostate cancer-induced osteolysis that using an inhibitor with 
high selectivity for MMP-2 and -9 reduced tumor growth, angiogenesis and the 
development of bone lesions 141.  Although, the use of prinomastat (an MMP-2 and 
MMP-9 selective inhibitor) has been shown to still induce joint pain, the execution of 
more studies focusing on identifying the contribution of individual MMPs in tumor-
induced osteolysis should lead to the development of therapies for patients presenting 
with incurable bone metastases. 
 
Aims of this dissertation 
The aims of this dissertation are to increase our understanding on how individual host 
MMPs contribute to mammary tumor growth and osteolysis.   
In a rat model of prostate tumor growth in the bone, Lynch and coworkers 
assessed the expression of 1200 genes at the tumor-bone interface and tumor area alone.  
Several genes showed a significant increased in their expression at the tumor-bone 
interface and interestingly, several MMPs such as MMP-2, -3, -7, -9 and -13 were 
particularly upregulated in comparison to the tumor area alone 116.  Furthermore, the 
authors demonstrated that MMP-7 significantly impacted prostate tumor growth-induced 
osteolysis via the solublization of RANKL which in turn could activate osteoclast 
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precursor cells 116.  Through the Orthopaedics and Rehabilitation Department at 
Vanderbilt, we obtained 11 human samples of breast-to-bone metastasis and expression 
of various MMPs were assessed by immunofluorescent staining (Table 3).  MMP-7 and 
MMP-9 presented a distinct localization pattern, mainly in mature osteoclasts at the 
tumor-bone interface.  Although, other stromal cells appeared to express MMP-7 and -9, 
breast tumor cells were largely negative for these two MMPs.  Human samples of breast-
to-bone metastases were also stained for MMP-2, -3 and -13 however, their pattern of 
expression appeared more diffuse throughout the tumor/stroma compartment.   
Since osteoclasts are the main cells responsible for bone resorption, we decided to 
investigate further the potential contributions of host-derived MMP-7 and MMP-9 in 
mammary tumor-induced osteolysis.  In addition, based on recent studies reporting the 
importance of host MMP-2 in osteoblast behavior and given the role of osteoblasts in 
osteoclast activation and function, we also examined the effect of host MMP-2 in 
mammary tumor growth and mammary tumor-induced osteolysis.  Based on these data, 
this dissertation focused on identifying the contributions of host MMP-2, -7 and -9 in 
mammary tumor-induced bone lesions.  The approach utilized was intratibial injection of 
mammary tumor cells in syngeneic and immunocompromized MMP deficient mice to 
investigate the contribution of individual host MMPs in mammary tumor growth and 
mammary tumor induced osteolysis in the bone. 
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Table 3. MMP expression in human breast-to-bone metastatases samples. 
MMP expression was assessed by immunofluorescent staining for specified MMP.  + 
indicates positive staining in the specific compartment (tumor or stroma) and – indicates 
an absence of staining throughout the sample. 
Sample 
MMP-2 MMP-7 MMP-9 MMP-13 
Tumor Stroma Tumor Stroma Tumor Stroma Tumor Stroma 
2-3-06 + + - + - + + + 
2-08-07 + + - + - + + + 
1-11-07 + + - + - + + + 
3-21-07 - - - - - - - + 
6-10-06 + + - + - + + + 
2-4-06 + + - + - + + + 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell culture 
Two independent syngeneic FVB mammary tumor cell lines derived from the polyoma 
virus middle T (PyMT) model of mammary tumorigenesis tagged with a luciferase 
reporter gene and designated, PyMT-Luc or PyMT-Dsred2 and 17L3C-Luc, were used in 
all studies 142.  A luciferase tagged 4T1 mammary tumor cell line was kindly provided by 
Dr. Swati Biswas of the Vanderbilt Center for Bone Biology (Aslakson et al, 1992). 
COS-7 cells were used for the LTBP-3 overexpression experiment (ATCC #CRL-
1651™).  All cell lines were cultured in DMEM (Gibco BRL, Long Island, NY) 
supplemented with 10%FBS (Atlanta Biologicals, Atlanta, GA) and 5 µg/ml puromycin 
(only for PyMT-Luc and 17L3C-Luc cells, Sigma-Aldrich, St Louis, MO) at 37oC, 5% 
CO2.  
 
Generation of PyMT-DsRed mammary tumor cell line 
PyMT cells were labeled with DSred Express through transduction with a lentiviral titer 
made by co-transfection of HEK293-T17 cells with a pPACK Packaging Plasmid Mix 
(System Biosciences) and a pLenti6-based (Invitrogen) lentivector construct modified to 
express DSred Express (construct obtained from Dr. Meenhard Herlyn, Wistar Institute). 
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After 24 hours in 10 % serum, tumor cells were then treated with 20 µg/ml blasticidin 
(Invitrogen) to select the infected cells. Once selected, PyMT-DsRed cells were 
maintained in 10 µg/ml blastocidin.  
 
Isolation of primary osteoblasts 
Calvaria from wild type or MMP-2 deficient 3 to 4 day-old pups were harvested in cold 
sterile 1X Phosphate buffered saline buffer (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.47 KH2PO4, pH 7.6) and stripped off the periosteum and sutures using a 
razor blade, only the parietal bone is used for the remaining of the isolation protocol .  
Calvaria were then subjected to three digestions (respectively 15 min, 30 min and 1 hour) 
in digestion buffer (α-MEM and 0.025% trypsin, Gibco BRL, Long Island, NY, 10mg/ml 
collagenase P, Roche), at 37oC with vigorous shaking every 15 min.  Isolated primary 
cells from the supernatants of the digestion were then maintained in α-MEM and 10% 
fetal bovine serum (Atlas Biologicals), 100 µg/ml penicillin/streptomycin (Invitrogen) 
and 250 unit/ml fungizone (Gibco, BRL, Long Island, NY).  Primary osteoblasts were 
plated at a density of 2x105 cells/well in 6 well-plates and 24 h after seeding; cells were 
cultured in serum starved α-MEM media.  After 24 h, conditioned media was collected, 
centrifuged at 1100 rpm to remove cellular debris and subsequently used for the MTT 
and soft agar colony formation assays described below. 
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Isolation of primary osteoclast precursor cells 
Bone marrow cells from tibias and femurs were isolated from 6 week-old wild type and 
MMP-2 deficient mice by flushing the cells with 1 ml of cold 1X PBS using a 25G5/8 
gauge needle. Isolated cells were centrifuged at 1,000 rpm and rinsed with 1 ml of 1X 
PBS.  CD11b positive cells were then isolated using Macs® Separation columns 
(Miltenyi Biotech) following the manufacturer’s protocol and plated in α-MEM and 10% 
fetal bovine serum (Atlas Biologicals), 100 µg/ml penicillin/streptomycin (Invitrogen) 
and 250 unit/ml fungizone (Gibco, BRL, Long Island, NY) for the migration and 
differentiation assays described below. 
 
Mice and genotyping 
All experiments involving animals were conducted after review and approval by the 
office of animal welfare at Vanderbilt University.  Immunocompromised recombinase 
activating gene-2 (RAG-2) null MMP-7 deficient mice were generated as previously 
described (Lynch et al, 2005). Wild type and MMP-2 and MMP-9 deficient mice in the 
FVB/N-Tg background were kindly provided by Dr. Lisa Coussens, Dept. of Pathology, 
University of California San Francisco.  All mice were weaned at 3 weeks of age and 
genotyped by PCR analysis.  Primers designed to identify RAG-2 null and wild type 
allele were described previously 143.  The PCR conditions for the amplification of mouse 
RAG-2 or mutant allele were 94oC 4 min for 1 cycle; 94, 58, 72oC 1 min each for 30 
cycles; 72oC 1 min for 1 cycle.  Primers designed to identify MMP-7 mutant or wild type 
allele were designed previously in the Matrisian laboratory, wild type allele: forward 
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primer 5’ AAT GAG CTG GCT GTG GAT CTG GT 3’, reverse primer 5’ GAG GGT 
TTG ATT TCT ATT TTC AG 3’. Primers for the mutant allele are forward primer 5’ 
CAT CGC CTT CTA TCG CCT TCT TG 3’, reverse primer 5’ TGC GTC CTC ACC 
ATC AGT CCA GTA 3’. The PCR cycle conditions for the amplification of mouse  wild 
type MMP-7 or the mutant allele were 95oC 15 min for 1 cycle; 94, 57, 72oC 1 min each 
for 4 cycle; 91, 57, 72o C 30 sec each for 28 cycles.  Double deficient RAG-2 null MMP-
7 null mice were used for the animal experiments described in this dissertation.  Primers 
designed to identify mutant MMP-9 allele are forward primer 5’ CTA AAG CGC ATG 
CTC CAG AC 3’ and reverse primer 5’ GAA GAG GTG ACT GCG ACT CC 3’.  
Primers used to identify wild type MMP-9 allele were generated previously in the 
Matrisian laboratory, forward primer 5’ GCA TAC TTG CGC TAT GG 3’ and reverse 
primer 5’ TAA CCG GTG CAA ACT 3’.  The PCR conditions for amplification of 
mouse wild type or mutant MMP-9 allele were 94oC 4 min for 1 cycle; 94, 58, 72oC 1 
min each for 30 cycles; 72oC 1 min for 1 cycle.  MMP-2 null mice were genotyped using 
gelatin zymography.  Serum was isolated from wild type and MMP-2 deficient animals.  
Serum samples mixed with sample buffer (10% SDS, 0.5M Tris-HCl pH 6.8, 30% 
glycerol, and 0.02% bromophenol blue) were separated on a 8% SDS-PAGE gel 
containing 3 mg/ml gelatin (Sigma-Aldrich, St Louis, MO).  The gel was then rinsed for 
15 min in 2.5% Triton X-100 buffer (Sigma-Aldrich, ST Louis MO), then incubated 
overnight in activation buffer (50 mM Tris-HCl, 10 mM CaCl2) and then stained for 1 
hour in staining buffer (0.5 % coomassie in 50 % methanol and 10 % acid acetic).  The 
gel was destained in distilled water until clear bands were visible. 
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Intratibial injection and in vivo quantitation of tumor growth 
PyMT-Luc, 4T1-Luc and 17L3-Luc tumor cells (2x105) in a 10µl volume of sterile PBS 
were injected into the tibia of anesthetized immunocompetent or immunocompromised 6 
week old mice that were wild type or deficient in MMP-2, MMP-7 or MMP-9. The 
contralateral limb was injected with 10µl of PBS alone and acted as a sham injected 
control for the bone remodeling due to the direct injection in the bone.  The IVISTM 
system (Caliper Life Sciences) was used to detect luminescence from the mammary 
tumor cells after intratibial injection.  Firefly luciferin (120mg/kg in sterile PBS, Gold 
Biotechnology, Inc.) was delivered retro-orbitally 1 to 2 minutes prior to imaging. Mice 
were imaged at 24 hours and every 3 days after surgery. Living ImageTM software 
(Calipers Life Sciences) was used to quantify the luminescence intensity in the tumor 
bearing limb over time.  Mice were sacrificed at specified time points post-surgery and 
both the tumor injected and contralateral control tibiae were harvested.  All animal 
studies were independently repeated at least three times. 
 
Histology 
De-identified human samples of frank osteolytic breast to bone metastasis (n=11) were 
collected by curettage with IRB approval from Vanderbilt University from 2005 to 2008.  
Fresh human breast-to-bone metastases, tumor and sham injected mouse tibiae were fixed 
overnight in 10% buffered formalin and decalcified for 3 weeks in 14% EDTA at pH 7.4 
with changes every 48-72 hours.  Tissues were embedded in paraffin and 5µm thick 
sections were cut. For MMP-7, MMP-9 and tartrate resistant acid phosphatase (TRAcP) 
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localization, the following technique was employed. Sections were rehydrated through a 
series of ethanols and then rinsed in tris buffered saline (TBS; 10mM Tris at pH 7.4, 
150mM NaCl) with Tween-20 (0.05%) (TBST).  For antigen retrieval, slides were 
immersed in a 20µg/ml solution of proteinase K according to the manufacturer’s 
instructions for 10 minutes at room temperature.  Following washing in TBS, tissue 
sections were blocked using standard blocking criteria (10 % serum of the appropriate 
specie in 1X TBS) for 1 hour at room temperature. MMP-7 144 or MMP-9 (Oncogene, 
Cambridge, MA) antibodies at a dilution of 1:100 were added in blocking solution 
overnight at 4oC.  Slides were washed extensively in 1X TBST prior to the addition of a 
species specific fluorescently labeled secondary antibody (Alexafluor 568nm, Invitrogen) 
diluted 1:1,000 in blocking solution for 1 hour at room temperature.  Slides were washed 
in TBS and then equilibrated in an acetate buffer as described 145. The ELF97 TRAP stain 
(Invitrogen) was diluted 1:1,000 in acetate buffer and slides were incubated for 15 
minutes at room temperature.  Following washing, slides were aqueously mounted in 
media (Biomeda Corp) containing 2μM DAPI (4´,6 diamidino-2-phenylindole) for 
nuclear localization.  For MMP-2 staining, no antigen retrieval was used, following 
washing in TBS, tissue sections were blocked using standard blocking criteria for 1 hour 
at room temperature. MMP-2 (Abcam) antibody at a dilution of 1/150 was added in 
blocking solution overnight at 4oC. Slides were washed extensively in TBST prior to the 
addition of a species specific anti-goat biotinylated IgG antibody (Vector Laboratories) 
diluted 1:1,000 in blocking solution for 1 hour at room temperature. Labeled cells were 
visualized using an avidin-biotin peroxidase complex (Vectastain ABC kit, Vector 
Laboratories) and 3,3′ –Diaminobenzidine tetrahydrochloride substrate (Sigma, St. Louis, 
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MO). Sections were counterstained with hematoxylin, dehydrated and permanently 
mounted. 
TRAcP was also detected using a colorimetric kit according to the manufacturer’s 
instructions (Sigma-Aldrich, St Louis, MO).  Gross anatomy of the mouse tibiae was 
assessed by hematoxylin and eosin (H&E) staining using a standard protocol.  
Proliferation (anti-phospho Histone H3, Upstate, Lake Placid, NY, 1:50 dilution, or 
Mcm2, Abcam, Cambridge, MA, 1:200 dilution) and apoptosis (anti-Caspase-3, Cell 
Signaling Technology, Danvers, MA, 1:400 dilution) were assessed by 
immunohistochemistry as described above. 
 
Micro computed tomography (µCT) and histomorphometric analyses 
For gross analysis of trabecular bone volume, formalin fixed tibiae were scanned at an 
isotropic voxel size of 12µm using a microCT40 (SCANCO Medical).  The tissue volume 
(TV) was derived from generating a contour around the metaphyseal trabecular bone that 
excluded the cortices.  The area of measurement began at least 0.2mm below the growth 
plate and was extended by 0.12mm.  The bone volume (BV) included all bone tissue that 
had a material density greater than 438.7 mgHA/cm3.  These analyses allowed for the 
calculation of the BV/TV ratio. The same threshold setting for bone tissue was used for 
all samples thus allowing for direct comparison between groups. 
For histomorphometry of the BV/TV ratio, three non-serial sections of tumor 
bearing and saline injected hind limbs were H&E stained to assess the ratio of BV/TV or 
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with TRAcP to assess osteoclast number per mm bone at the tumor bone interface using 
Metamorph® software (Molecular Devices). 
 
Immunoprecipitation, Immunoblotting and ELISA 
Tumor and sham injected tibias from wild type or MMP null animals were harvested at 
specified time points post-injection and flash frozen in liquid nitrogen.  Tissue 
homogenates were generated by mortar and pestle and total protein was subsequently 
extracted using a standard protein lysis buffer (0.1 % sodium dodecyl sulfate, 0.5 % 
sodium deoxycholate, 1 % Triton X100, 20 mM Tris pH 7.5, 150 mM NaCl) containing a 
complete protease inhibitor cocktail (Roche).  Lysates were then centrifuged at 14,000 
rpm for 10 min and supernatant was then isolated.  Protein concentration in isolated 
samples was quantitated using a bicinchoninic acid (BCA) assay as per manufacturer’s 
instructions (Pierce).  For immunoprecipitation and quantitation of soluble RANKL in the 
tumor-bone microenvironments, equal concentrations of total protein (1mg) in 1ml of 
PBS were pre-cleared with 10µl of protein-G-sepharose beads (Amersham Biosciences) 
for one hour at 4oC.  Pre-cleared lysates were then incubated with 2µg of antibody 
directed to the N-terminus of RANKL (Santa Cruz Biotechnology) for 1 hour at 4oC with 
rocking prior to the addition of 10µl of protein-G-sepharose beads. Subsequently, 10µl of 
protein G-sepharose beads were added to the samples and the bead-antibody-protein 
complexes were allowed to form overnight at 4oC.  A nutator was used during all steps 
for agitation.   The complexes were washed extensively (100mM NaCl, 50mM Tris-HCl, 
pH7.5, 0.5% NP-40) and then boiled in sample buffer (10% SDS, 0.5M Tris-HCl pH 6.8, 
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30% glycerol, 1% β-mercaptoethanol and 0.02% bromophenol blue) for 10 minutes prior 
to loading on to a 15% SDS-PAGE gel.  Recombinant RANKL (RnD Systems, 
Minneapolis, MN) or MMP-7 solubilized RANKL (10µg recombinant RANKL 
incubated with 100ng active MMP-7 (Calbiochem, LaJolla, CA) for 1 hour at 37oC) as 
previously described (Lynch et al, 2005) were added as positive controls for the 
molecular weight of MMP solubilized RANKL.  Proteins were transferred to 
nitrocellulose membranes and blocked for 1 hour at room temperature (5% milk powder 
in 1xTBS; 5mM Tris-HCL pH 7.4). The blots were then panned with an antibody 
directed to the N-terminus of RANKL (1: 1,000 dilution; Axxora LLC in 5% milk in 
1xTBST (TBS with 0.05% Tween 20)) overnight with rocking at 4oC.  The following 
day, blots were washed extensively with 1X TBST prior to the addition of a secondary 
infra-red labeled anti-mouse antibody (1: 5,000 dilution in 1xTBST, Rockland Inc.) for 1 
hour at room temperature.  After washing in 1xTBST, blots were developed and bands of 
interest were quantitated using the Odyssey system (LI-COR Biosciences, Lincoln, NE).  
For LAP and LTBP-3 immunoblotting, equal amounts of protein were loaded on either 4-
12% gradient SDS-PAGE (Invitrogen) or 6 % SDS-PAGE non-denaturing gels 
respectively.  Immunoblotting protocol followed was identical as described above; 
primary antibodies used were goat anti-human LAP (R&D System, dilution 1:1,000) and 
rabbit specific anti-mouse LTBP-3 (anti-L3C, dilution 1:1,000, kindly provided by Dr D. 
Rifkin, Dept of Cell Biology and Medicine, New York University School of Medicine).  
Secondary infra-red labeled anti-goat or anti-rabbit antibodies (1:5,000, Rockland Inc) 
were used for detection of the antibody/antigen complex in the dark for 1 hour at room 
temperature.   
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ELISA was also used for the quantitation of soluble RANKL and TGF-β in 
samples according to the manufacturer’s instructions (Quantikine, R&D Systems). 
 
MTT Assay 
Quantitation of viable PyMT-Luc cells treated with conditioned media from primary 
osteoblast wild-type or MMP-2 deficient mice was assessed using tetrazolium-based 
colorimetric assay (MTS, Promega Corporation).  Tumor cells were plated in 96-well 
plates at a density of 1000 cells/well and 24 h after seeding, cells were treated with 100 
µl of either serum starved media, conditioned media from primary osteoblasts isolated 
from either wild type or MMP-2 deficient mice.  After 24 and 48h of treatment, 20 µl of 
MTS was added to each well of cells, and the plate was incubated for 3 h at 37°C.  
Spectrophotometric absorbance of each sample was measured at 490 nm using a MRX 
revelation microplate reader (Dynex Technologies). Experiments were performed in 
quadruplicate.   
 
Soft agar colony formation assay 
PyMT-Luc cells were plated at a density of 1.5x103 cells/well in 24 well-plates in soft 
agar containing α-MEM, 5% fetal bovine serum, 0.7% agarose (Fischer, cat. No. BP164).  
Tumor cells were treated with 400 µl of 5% serum α-MEM, 5% serum and conditioned 
media from wild type or MMP-2 null primary osteoblasts or 1ng/ml TGF-β and the 
media was changed 3 times a week.  After 10 days of culture, cells were stained 
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overnight at 37oC by addition of 0.1mg/ml p-iodonitrotatrazolium (Sigma-Aldrich, St 
Louis, MO) to the media.  Numbers of colonies for each condition were counted on 100X 
photomicrographs.  Experiments were performed in quadruplicate.  
 
Migration assay of osteoclast precursor cells  
CD11b positive cells were plated at a density of 105 cells/well in the upper well of a 
transwell (Corning Inc., 5µm pore size) in 500 µl of serum free α-MEM media. Cells 
were allowed to migrate towards the lower well of the transwell (1 ml of chemotactic 
gradient (10 % serum-α-MEM) or serum-free media as control) for 5 hours at 37oC.  
CD11b positive cells that migrated through the membrane were harvested in the lower 
well and counted.  Experiments were performed in triplicate. 
 
Differentiation of osteoclast precursor cell assay 
CD11b positive cells isolated from 6 week-old wild type and MMP-2 deficient bone 
marrow cells were plated in 48 well plate in 10 % serum-α-MEM media at a density of 
5x105 cells/well. The following day, cells were treated with 75 ng/ml RANKL (R&D 
system) and 30 ng/ml M-CSF (R&D system) in 500 µl of 10 % serum-α-MEM media. 
Media was changed every 3 days for a 15 day period. At the end of the assay, cells were 
fixed in ice-cold methanol and stained using a colorimetric TRAcP kit (Sigma-Aldrich, St 
Louis, MO) and counter stained in hematoxylin.  Multinucleated (more than 3 nuclei) 
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TRAcP cells were counted in 8 random field acquired using a 10X microscopic objective 
for each conditions. Experiments were performed in quadruplicate. 
 
COS-7 cells transfection and LTBP-3 digestion 
COS-7 cells were transiently transfected with a full length LTBP-3 cDNA construct and 
human TGF-β1 cDNA (kindly provided by Dr Rifkin, Dept of Cell Biology and 
Medicine, New York University School of Medicine) using Superfect (QIAGEN).  COS-
7 cells were plated at a density of 105 cells/well in a 6 well plate the day prior the 
transfection.  Cells were then incubated in transfection mix (30 µl of superfect reagent, 
0.5 µg of each constructs and 500 µl of DMEM and 10% FBS) overnight.  The next day, 
transfected COS-7 cells were incubated for 48 hours in serum starved DMEM media.  40 
µl conditioned media was then incubated for 3 hours at 37oC in presence of 300 ng of 
recombinant human MMP-2 (Calbiochem) or for 1 hour in presence of 150 ng of plasmin 
(Sigman-Aldrich, St Louis, MO).  Samples were then analyzed by immunoblotting for 
LTBP-3 as described above. 
 
Flow cytometry analysis 
PyMT-DsRed2 cells were intratibially injected into FVB wild type or MMP-2 deficient 
mice. After 3 days, tumor injected tibias were flushed with 500 µl of sterile PBS 1X 
using a 25G5/8 gauge needle.  Harvested cells were then centrifuged at 2000 g for 5 min 
and then resuspended in 1 ml of red blood cell lysis buffer (8 mM NH4Cl, 5 mM KHCO3) 
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for 5 min at room temperature. Cells were centrifuged at 2000 g for 5 min and 
resuspended in 1 ml of sterile PBS 1X. 106 cells were fixed and permeablized for flow 
cytometry analysis using BrdU Flow kit protocol (BD PharmingenTM, San Jose, CA).  
Fixed and permeabilized cells were then incubated in presence of anti-mouse 
CD16/CD52 (mouse BD Fc BlockTM, BD pharmingenTM, San Jose, CA, 1:20 dilution) for 
10 min on ice.  Primary antibodies, rabbit anti-mouse cleaved caspase-3 antibody (Cell 
Signaling Technology, Danvers, MA, 1:100 dilution)  and alexa Fluor® 647 Rat anti-
Histone H3 antibody (BD PharmingenTM, San Jose, CA, 1:4 dilution) were added to the 
samples and incubated for 30 min on ice. Cells were then centrifuged at 2000 g for 5 min 
and resuspended in 500 µl of staining buffer provided by the BrdU flow kit and incubated 
in presence of secondary antibody Pacific BlueTM goat anti-rabbit IgG (Invitrogen, 
Carlsbad, CA, dilution 1:400 dilution) for 30 min.  Cells were centrifuged at 2000 g for 5 
min and resuspended in 500 ul of 1 % bovin albumin serum in PBS 1X and strain them 
trough a 35 µm nylon mesh and analyzed using 5-laser BD LSRII flow cytometer. 
 
Statistical analyses 
For in vivo data, statistical analysis was performed using Anova and Bonferroni multiple 
comparison tests using GraphPad Prism Inc. Software. In vitro, statistical significance 
was analyzed using a student’s t test. A value of p < 0.05 was considered significant. 
Data are presented as mean ± standard deviation (SD). 
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CHAPTER III 
 
CONTRIBUTIONS OF OSTEOCLAST-DERIVED MMPS TO MAMMARY TUMOR 
GROWTH IN THE BONE MICROENVIRONMENT 
 
Introduction 
Osteoclasts are critical for the completion of the vicious cycle since they are the principal 
cells involved in the direct resorption of the mineralized bone matrix.  Therefore, 
understanding how osteoclast precursors are recruited to areas requiring bone remodeling 
and understanding the mechanisms involved in controlling their maturation and activation 
is key for the development of new therapies that can effectively stop the vicious cycle.  
Osteoclasts express a variety of proteases including the cysteine protease, cathepsin-K 
and MMPs 77.  While cathepsin-K activity is critical for bone resorption 28, the role of 
osteoclast-derived MMPs is less clear.  MMPs are often overexpressed by the stromal 
cells rather than the tumor 86.  In the context of the tumor-bone microenvironment, pre-
clinical animal studies have demonstrated the efficacy of broad spectrum MMPIs in 
preventing tumor growth and tumor induced osteolysis 137-139.  However, the failure of 
MMPIs in human clinical trials prevents their application for the treatment of lytic bone 
metastases 135.  A main conclusion derived from these trials was the necessity for 
defining the precise roles of individual MMPs in disease processes that would allow for 
the generation of highly selective MMP inhibitors.  To this end, we have assessed the 
expression of MMPs in human clinical samples of osteolytic breast to bone metastasis.  
While the expression of many MMPs was noted throughout the tumor/stroma, MMP-7 
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and MMP-9 were highly localized to bone resorbing osteoclasts.  Given the importance 
of osteoclasts in driving the vicious cycle, the current study focused on determining if 
and how these osteoclast derived MMPs impact tumor-induced osteolysis. 
 
Results 
 
MMP-7 and MMP-9 are expressed by osteoclasts in human breast to bone metastases 
Previous observations using an animal model of tumor-bone interaction identified several 
MMPs as being highly expressed at the tumor-bone interface compared to the tumor area 
alone, namely MMP-2, -3, -7, -9 and -13116 (unpublished data).  The expression of these 
MMPs was examined in human cases of frank breast to bone metastasis (n=11).  
Interestingly, MMP-7 and MMP-9 were largely localized to the majority of mature 
TRAcP positive multinucleated osteoclasts at the tumor-bone interface in human samples 
containing areas of osteolysis (10 of 11 samples) (Figure 5A-C).  Other cells in the 
stromal compartment stained positively for MMP-7 and MMP-9 but remarkably, the 
tumor cells were negative for these metalloproteinases.  MMP-2, -3 and -13 were also 
detected but their expression was diffuse throughout the tumor/stroma compartment 
(Figure 16 and data not shown).  Since osteoclasts are the principal cells involved in bone 
resorption, we examined whether the ablation of host derived MMP-7 or MMP-9 would 
impact the vicious cycle in terms of mammary tumor growth and/or mammary tumor 
induced osteolysis.  
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Host derived MMP-9 does not contribute to tumor growth or tumor induced osteolysis 
MMP-9 has previously been reported to be localized to osteoclasts and MMP-9 null 
animals have been identified as having a delay in osteoclast recruitment during the 
development of long bones 75.  Therefore, we initially tested the role of host derived 
MMP-9 in tumor growth or tumor induced osteolysis.  Consistent with our observations 
in human samples, bone resorbing osteoclasts in wild type mice were positive for MMP-9 
expression by immunofluorescent staining while as expected, MMP-9 was not detected in 
MMP-9 null osteoclasts (Figure 6A).  Since MMP-9 null animals have a transient 
developmental bone phenotype, we determined the baseline trabecular bone volume as a 
function of tissue volume (BV/TV) in wild type and MMP-9 null animals at 6 weeks of 
age which was the proposed time-point for introduction of the PyMT-Luc tumor cells.  
No difference in the BV/TV between the wild-type and MMP-9 null animals was 
observed (Figure 6B). 
To assess the contribution of host MMP-9 in mammary tumor growth in the bone 
microenvironment, the PyMT-Luc tumor cells, in which MMP-9 expression is 
undetectable in vivo 146, were injected into the tibia of syngeneic FVB wild-type or 
MMP-9 null mice.  Surprisingly, quantitation of the bioluminescent signal from the tumor 
cells showed no difference in the tumor growth rate between the MMP-9 null and wild 
type control mice (Figure 7A).  With respect to tumor induced osteolysis, analysis of the 
BV/TV ratio by high resolution µCT demonstrated that the tumor injected tibias of wild-
type and MMP-9 null were significantly lower (p<0.05) than their respective sham 
injected control counterparts (Figure 7B and C).  However, a direct comparison of the
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BV/TV ratios between the wild-type and MMP-9 null tumor injected limbs revealed no 
difference in BV/TV ratios (Figure 7B and C).  Furthermore, no difference in tumor 
growth as assessed by phospho histone H3 for proliferation and cleaved caspase-3 
immunohistochemistry for apoptosis (Figure 7DC and E) or trabecular bone volume by 
histomorphometry was observed between the wild type and MMP-9 null groups (Figure 
7B).  These experiments, with similar sized groups, were repeated on several occasions 
with similar results.  These results using the intratibial model suggest that host MMP-9 
does not contribute to mammary tumor growth in the bone or tumor- induced osteolysis 
and are consistent with studies examining the role of host MMP-9 in the prostate cancer-
bone microenvironment 147. 
 
Host MMP-7 contributes to mammary tumor growth in the bone microenvironment 
This is the first report to document the expression of MMP-7 in human breast to bone 
metastases and in human osteoclasts (Figure 5), although MMP-7 has previously been 
identified in rodent osteoclasts 116. Recapitulating observations in human clinical 
samples, MMP-7 expression was identified in wild type murine osteoclasts and not in 
MMP-7 null osteoclasts (Figure 8A).  Given that MMP-7 expression by osteoclasts is a 
relatively recent observation, studies into defining roles for MMP-7 in skeletal 
development have not been explored thus far. Therefore, prior to testing the impact of 
host derived MMP-7 on the vicious cycle, the trabecular bone volume in non-injected 6 
week old immunocompromised wild type and MMP-7 null animals was examined using 
high resolution µCT.  Our results revealed no significant difference in the BV/TV ratio 
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between wild type and MMP-7 null animals suggesting that at this time point, MMP-7 
null animals do not display an obvious bone phenotype in comparison to the wild type 
controls (Figure 8B). 
To determine the contribution of host MMP-7 to mammary tumor growth in the 
bone microenvironment, PyMT-Luc cells were injected into 6 week old wild-type or 
MMP-7 null mice. Quantitation of the bioluminescent signal from the PyMT-Luc cells 
demonstrated a significant decrease in the tumor growth rate in MMP-7 null mice 
compared to the wild type controls (Figure 9A).  These experiments with similar sized 
groups in terms of animal numbers were independently repeated on four occasions and 
similar observations were noted. To further investigate the potential role of MMP-7 in 
tumor growth, tumor proliferation and apoptosis were assessed by immunohistochemistry 
for phospho-histone H3 and cleaved caspase-3, respectively, in multiple sections from at 
least five animals per group (Figure 9B and C). Surprisingly, no difference in tumor 
proliferation was observed between the wild type and MMP-7 null groups, however, 
tumor apoptosis was significantly higher in MMP-7 null mice compared to the wild type 
controls (p<0.05).  Similar findings with respect to the impact of host MMP-7 on tumor 
growth using the 4T1-Luc cell line were also observed (Figure 10A-C).  These results 
suggest that host-derived MMP-7 significantly contributes to mammary tumor growth in 
the bone by enhancing tumor cell survival.  
 
Host derived MMP-7 contributes to mammary tumor induced osteolysis 
The vicious cycle of tumor-bone interaction suggests that tumor growth/survival is
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dependent on osteoclast mediated bone resorption.  Since MMP-7 is primarily localized 
to bone resorbing osteoclasts in the tumor-bone microenvironment, we assessed whether 
a lack of MMP-7 in osteoclasts impacted tumor induced osteolysis.  Analysis of the 
BV/TV ratios from wild type and MMP-7 null tumor injected tibias using µCT (Figure 
11A) and histomorphometry (Figure 11B) revealed that the MMP-7 null group had a 
significantly higher amount of trabecular bone which is in keeping with our tumor growth 
data, i.e. less tumor growth in the MMP-7 null animal would lead to less osteolysis.  X-
ray analysis also revealed a significantly lower tumor volume in the MMP-7 null animals 
compared to wild type controls (Figure 11C).  Studies using the 4T1-Luc cell line also 
demonstrated that host derived MMP-7 significantly impacted tumor induced osteolysis 
(Figure 12A and B).  These results demonstrate for the first time that host derived MMP-
7 significantly impacts mammary tumor induced osteolysis. 
 
MMP-7 mediates RANKL solubilization in the tumor-bone microenvironment 
Next, we explored the potential molecular mechanisms through which osteoclast derived 
MMP-7 was impacting tumor induced osteolysis.  Given the acidity of the resorption 
lacunae (pH<4) and the neutral activity profile of MMP-7, we suggest that MMP-7 does 
not function in direct bone matrix degradation but in the processing of factors that impact 
cell-cell communication within the tumor-bone microenvironment. MMP-7 has 
previously been shown to process a number of growth factors and cytokines to soluble 
active forms including members of the tumor necrosis factor family (TNF), TNF-α, Fas 
ligand (FasL) and RANKL 72, 116, 148.  RANKL is essential for osteoclastogenesis and is a  
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potent chemotactic molecule for monocytes and osteoclast precursor cells 149, 150. 
Therefore, we investigated if MMP-7 solubilization of RANKL was relevant in our 
model. 
ELISA analysis revealed lower levels of total RANKL (membrane bound and 
soluble) in the tumor injected tibias of MMP-7 null mice compared to wild type control 
mice (Figure 13A) while no difference was observed in the sham injected control 
counterparts of each group (data not shown).  Similar levels of OPG, a soluble decoy 
receptor of RANKL, were found in the wild-type and MMP-7 null animals and were not 
present at a high enough concentration to interfere with the detection of RANKL by 
ELISA (data not shown).  Immunoprecipitation and immunoblotting for soluble RANKL 
also revealed significantly lower levels of soluble RANKL in PyMT-Luc and 4T1-Luc 
tumor injected MMP-7 null animals compared to wild type controls as assessed by 
densitometry (Figure 13B and 14A). 
Interestingly, soluble RANKL could still be detected in the tumor bearing limbs 
of MMP-7 null animals. This suggests that RANKL solubilization is still occurring in the 
absence of MMP-7.  We and others have previously identified that other 
metalloproteinases such as MMP-1, -3, -14, ADAM-17 and the serine protease cathepsin 
G are capable of processing RANKL to a soluble active form and therefore, these 
proteases may also be playing a role in the solubilization of RANKL in our model 116-118, 
151.  However, since the levels of RANKL are significantly lower in the MMP-7 null 
mice, we suggest that MMP-7 is the dominant protease involved in RANKL 
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solubilization.   
Next, since a decrease in the amount of soluble RANKL was detected in the 
tumor bearing limbs of the MMP-7 null animals, we asked if there was concomitant 
decrease in the number of osteoclasts in the MMP-7 null tumor-bone microenvironment. 
We observed significantly lower numbers of TRAcP positive multinucleated osteoclasts 
per unit length of tumor-bone interface in the MMP-7 null animals compared to the wild 
type controls (Figure. 13C). Significantly lower numbers of osteoclasts were also 
recorded in MMP-7 deficient animals injected with 4T1-Luc cells compared to wild type 
controls (Figure 14B). Given the importance of RANKL in mediating osteoclastogenesis, 
these data suggest that MMP-7 mediates mammary tumor induced osteolysis by 
impacting the availability of a key factor for osteoclastogenesis, RANKL. 
 
Conclusions 
Understanding the molecular mechanisms that control the vicious cycle is key for the 
development of new therapeutics that will be effective not only in treating bone 
metastases but also in curing them. In the current study, we found that in human cases of 
breast to bone metastasis, osteoclasts were a rich source of MMP-7 and MMP-9. 
Interestingly, our studies using two unrelated osteolytic inducing tumor cell lines (PyMT-
Luc and 4T1-Luc) revealed that only MMP-7 appeared to contribute to mammary tumor 
growth and tumor induced osteolysis in the bone microenvironment. Furthermore, our 
data suggests that MMP-7 solubilization of the osteoclastogenic factor RANKL is the 
principal molecular mechanism underlying these observations. Previously, we have 
58 
 
identified that MMP-7 processing of RANKL results in the generation of an active 
soluble form that can promote osteoclast maturation and activation 116. Therefore, in the 
context of the breast to bone metastases we hypothesize that in the absence of MMP-7 
solubilized RANKL, there is a resultant decrease in osteoclast maturation and bone 
resorption at the tumor-bone interface that in turn results in a decrease in bone derived 
growth factors that impact tumor growth (Figure. 15).  These data suggest that MMP-7 
inhibition using a selective approach may be efficient for the treatment of breast to bone 
metastases. 
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CHAPTER IV 
 
CONTRIBUTIONS OF OSTEOBLAST-DERIVED MMP-2 TO MAMMARY TUMOR 
GROWTH-INDUCED BONE LESIONS 
 
Introduction 
Osteoblasts are the cells responsible for the synthesis of the bone and the deposition of 
growth factors such as TGF-β and IGFs in the bone matrix 11.  These factors are 
complexed in latency proteins and therefore, the proteases that govern their release and 
activation are of great importance.  TGF-β and IGFs are crucial players in the vicious 
cycle as they have been shown to promote the differentiation of osteoclast precursor cells 
into multinucleated mature osteoclasts 23.  By activating osteoclasts, osteoblasts promote 
osteolysis and the release of growth factors in the tumor-bone microenvironment 87.  
Many studies on breast tumor growth in bone have focused on the osteoclast and how to 
inhibit osteoclast function in a bid to halt bone resorption.  However, with the exception 
of tumor effect on the expression of osteoclastogenic factors by the osteoblasts such as 
RANKL, little attention has been given to osteoblast-mediated tumor growth in vivo.   
Osteoblasts have been reported to express several MMPs but the contribution of 
osteoblast-derived MMPs to the vicious cycle has not been explored to date 81, 152-157.  
MMPs have been implicated as important mediators of cell-cell communication, 
therefore investigating their contributions to osteoblast functions in a tumor setting is of 
interest.  
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In assessing MMP expression in human and murine breast-to-bone metastases, we 
found that one MMP in particular, MMP-2 was localized to osteoblasts, osteocytes and 
other cell types throughout the tumor/stroma compartment.  This localization of MMP-2 
in osteoblast and osteocyte is in keeping with studies examining MMP-2 roles in skeletal 
development.  Thus far, the contribution of MMP-2 in the pathological context of the 
metastatic tumor-bone microenvironment has not been examined.  Given the importance 
of the osteoblasts in driving the vicious cycle, the current study focused on determining if 
and how host-derived MMP-2 impacted tumor induced osteolysis. 
 
Results 
 
Expression of MMP-2 in human and mouse samples of breast to bone metastasis 
A recent study reported the high expression of several MMPs (MMP-2, -3, -7, -9 and -13) 
at the tumor-bone interface in a murine model of tumor growth in the bone 116.  In human 
samples of breast to bone metastasis and tumor bearing limbs of wild type animals, 
expression of these 5 MMPs was assessed. As shown in Figure 5, MMP-7 and MMP-9 
were primarily localized in TRAcP positive multinucleated osteoclasts present at the 
tumor-bone interface.  In contrast, MMP-2 expression appeared more diffuse throughout 
the tumor/stroma compartment (Figure 16A-B) but osteoblasts and osteocytes were 
consistently positive for MMP-2 (Figure 16A-B).  Interestingly, osteoclasts in the tumor-
bone microenvironment were rarely positive for MMP-2 (Figure 16A). These 
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observations are in agreement with recent studies reporting osteocyte and osteoblast 
expression of MMP-2 in normal murine bone 68, 69. Since osteoblasts have a central role 
in promoting osteoclast activation and subsequent bone resorption in the vicious cycle, 
we examined the potential impact of the ablation of host MMP-2 in a murine model of an 
osteolytic tumor-bone microenvironment. 
 
Host MMP-2 significantly impacts mammary tumor growth in the bone 
Trabecular bone is a highly metabolically active bone, rich in growth factors, that 
undergoes continuous remodeling 8.  During tumor-induced osteolysis, trabecular bone is 
typically the first bone to be resorbed 158.  As MMP-2 deficient mice have a transient 
bone phenotype, we determined the baseline of trabecular bone volume/tissue volume 
(BV/TV) ratios in tibias of 6 week old wild type and MMP-2 deficient animals and found 
not difference between the two groups using high resolution µCT (Figure 16C). 
 To determine the contribution of host derived MMP-2 in mammary tumor growth 
in the bone, the PyMT-Luc mammary tumor cell line which expresses MMP-2 in vitro 
(Figure 16D), was injected into the tibia of syngeneic immunocompetent FVB wild type 
and MMP-2 deficient animals.  Quantitation of the bioluminescent signal from the 
PyMT-Luc tumor cells showed an increased tumor growth rate between the wild type and 
MMP-2 null mice from day 3 post-injection onwards (Figure 17A and B). These  
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Figure 17. Host-derived MMP-2 impacts mammary tumor growth in the bone
microenvironment. A-B: PyMT-Luc cells were intratibially injected into FVB wild type (WT; 
n=10) or MMP-2 null (MMP-2-/-; n=10) mice. The contralateral limb received a sham injection o
 
f 
saline and luciferase activity was assessed as a measure of tumor growth in WT and MMP-2-/-
animals. C: 17L3C-Luc cells were intratibially injected into FVB wild type (WT; n=10) or MMP-
2 null (MMP-2-/-; n=10) and tumor growth was assessed by bioluminescent imaging modality. D:
PyMT-Luc cells were intratibially injected into FVB wild type (WT; n=10) or MMP-2 null 
(MMP-2-/-; n=10) mice and tumor growth was followed for 15 days for WT mice and 25 days for 
MMP-2 null mice. E: Tumor proliferation and apoptosis was assessed by immunohistochemical 
staining for Mcm2 and cleaved caspase-3 respectively, in tumor bearing tibias of WT and MMP-
2-/- deficient mice, at 3 days post-surgery. F: At 6 days after injection, tumor proliferation and 
apoptosis was determined by immunohistochemical staining for respectively, MCM2 and cleaved 
caspase-3 on tumor bearing limbs of WT and MMP-2-/- deficient mice. Data are mean ± SD; n.s. 
implies a non-significant p value (p>0.05). 
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experiments with similar numbers of animals per group were conducted independently on 
several occasions and similar results were observed. The observed result on tumor growth 
was confirmed using another independent mammary tumor cell line, 17L3C-Luc cells 146 
( Figure 17C).  To delineate whether reduced tumor growth was due to survival or slow 
growth rate in vivo, tumors in the MMP-2 deficient animals were imaged for at least 25 
days.  The bioluminescent signal remained significantly less than that obtained in the 
wild type mice throughout the entire time period (Figure 17D).  These data suggested that 
perhaps host MMP-2 was important for the initial survival and establishment of tumor 
cells.   
To further analyze the impact of host MMP-2 to mammary tumor growth in the 
bone, we first decided to use a flow cytometry approach to specifically determine tumor 
versus host proliferation and apoptosis.  PyMT cells expressing Dsred were intratibially 
injected into wild type and MMP-2 deficient mice therefore.  Three days after surgery, 
tumor injected tibias were harvested and proliferation and apoptosis were assessed by 
flow cytometry using phospho Histone H3 and cleaved caspase-3 specific antibodies 
coupled with fluorophores (and pacific blue, respectively).  Therefore, tumor proliferative 
cells will be Dsred/ Alexa fluor® 647 positive and tumor apoptotic cells will be 
Dsred/pacific blue positive.  However, we determined that FVB bone marrow cells 
contains a sub population of autofluorescent cells (less than 2 % of total cells) conferring 
a high background signal which did not allow for an accurate assessment of tumor 
proliferation and apoptosis.  As a result, immunohistochemical stainings for Mcm2 and 
cleaved caspase- 3 were performed to assess tumor proliferation and apoptosis, 
respectively.  No difference in tumor proliferation was observed between the two groups 
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of animals at numerous time points (Figure 17E and F).  However, MMP-2 deficient mice 
showed a significant higher level of apoptotic tumor cells as early as 3 days after 
intratibial injection compared to wild type mice (Figure 17E).  Furthermore, at 6 days 
post-injection, the apoptotic tumor levels remained significantly higher in the MMP-2 
deficient animals compared to controls and tumor proliferation did not differ between the 
two groups of animals (Figure 17F).  These data show for the first time that host-MMP-2 
impacts tumor growth in the bone.  In addition host MMP-2 mediates its effect on tumor 
growth by enhancing tumor survival as early as 3 days post-injection and this high rate of 
apoptosis observed in the MMP-2 deficient mice persisted until day 6.  
 
Host MMP-2 contributes to mammary tumor growth induced osteolysis 
In the tumor-bone microenvironment, pathological bone remodeling requires osteoblast-
mediated activation of osteoclasts.  Osteoblasts are crucial for the induction of osteoclast 
activation via the expression of osteoclastogenic factors such as RANKL and M-CSF 
resulting in an extensive bone resorption that is thought to enhance tumor growth 10. 
Since a decrease in tumor growth was observed, we next assessed whether there was a 
concomitant decrease in osteolysis in the MMP-2 null tumor-bone microenvironment.  
High resolution µ-CT and histomorphometry analyses of the BV/TV ratios of wild type 
and MMP-2 deficient mice were performed at the end of the study period.  Tumor 
bearing limbs of wild type mice showed a significant decrease of the trabecular bone 
content compared to tumor injected tibias of MMP-2 deficient animals (Figure 18 A-B).  
These results demonstrate a decrease in tumor-induced bone resorption in the MMP-2  
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 Figure 18. Tumor mediated osteolysis is attenuated in the absence of host derived MMP-7. A: µCT 
scans of trabecular bone from tumor bearing and sham injected limbs of WT and MMP-2-/- mice allowed 
for the calculation of the BV/TV ratio. B:  Representative H&E stained photomicrographs of tumor bearing 
tibias from WT and MMP-2-/- mice. Scale bars are 1mm. The ratio of trabecular bone volume (BV) to 
tissue volume (TV) was determined several non-serial sections of tumor injected tibias obtained from WT 
(n=8) and MMP-2 null animals (n=8). C: Representative radiographic images from tumor injected WT and 
MMP-2-/- animals at day 9. Arrow indicates lytic tumor lesions in the wild type animals. The tumor volume 
(TuV) over tissue volume (TV) for tumor injected limbs of WT and MMP-2-/- animals was assessed. Data 
are mean ± SD. Asterisk denotes that p<0.05 while n.s. indicates a non-significant p value. 
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deficient mice compared to the wild type controls.  In addition, X-ray analysis revealed 
that MMP-2 deficient mice have a significantly lower tumor burden compared to the wild 
type control mice which is in agreement with our tumor growth and histomorphometry 
data (Figure 18C).   
As osteoclasts are the bone cells responsible for osteolysis, the number of mature 
osteoclasts was assessed in both groups of animals by counting the number of TRAcP 
positive multinucleated osteoclasts in several non-consecutive sections from multiple 
animals.  A significantly higher number of osteoclast per unit length of bone was 
observed in tumor injected tibia of wild type mice compared tumor bearing limbs of 
MMP-2 deficient animals (Figure 18D). This decrease in osteoclast number in the MMP-
2 deficient mice is in agreement with the higher content of trabecular bone and the 
decreased tumor growth rate, i.e. less tumor growth induces less bone resorption 
therefore, a lower number of mature osteoclasts.  
 Although we did not observe MMP-2 localization in osteoclasts, we tested 
whether absence of MMP-2 could affect osteoclast maturation and activation.  Osteoclast 
precursor cells (CD11b positive cells) were isolated from wild type and MMP-2 deficient 
mice and their ability to migrate towards a chemokine gradient (10 % serum) was 
assessed in a transwell assay (Figure 19A).  No difference between wild type and MMP-2 
deficient osteoclast precursor cells was observed in terms of number of migrating cells 
(Figure 19A).  The capacity of wild type and MMP-2 deficient CD11b positive cells to 
respond to osteoclast differentiating factors such as RANKL and M-CSF was tested 
(Figure 19B).  The same number of TRAcP positive cells was found in MMP-2 deficient  
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osteoclast precursor cells treated with RANKL and M-CSF compared to wild type cells 
(Figure 19B).  Therefore demonstrating that absence of MMP-2 does not impact the 
ability of osteoclast precursor cells to migrate towards a chemokine gradient and 
differentiate in presence of osteoclast activating factors.   
To address how host MMP-2 impacts tumor survival and tumor-induced 
osteolysis, we focused our attention on the osteoblasts since 1) they are a rich source of 
MMP-2 and 2) they are the common link in the vicious cycle between tumor growth and 
osteoclast recruitment, maturation and activation.  We initially decided to examine 
tumor/osteoblast interactions since the contribution of MMP-2 in this setting has thus far,  
not been explored.  
 
Osteoblast-derived MMP-2 mediates mammary tumor survival in the bone via the release 
of active TGF-β 
Given that MMP-2 has been shown to impact osteoblast function and that our human and 
mouse tissues samples showed an osteoblast localization of MMP-2, we determined if 
osteoblast-derived MMP-2 could mediate tumor growth and survival.  In order to assess 
this, we pursued a more straightforward in vitro approach.  The effect of conditioned 
media from wild type and MMP-2 deficient primary osteoblast to modulate PyMT-Luc 
cells growth and survival was assessed using MTT growth and clonogenic soft agar 
assays (Figure 20A and B).  Clonogenic assay was developed in the mid 1950s by Puck 
and Marcus to assess the ability of single mammalian cells to form colonies 159.  Since,  
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then, this assay, slightly modified had become the ‘gold standard assay’ in radiology to 
assay the efficacy of radiation treatment to induce apoptosis in tumor cells 160.  
Clonogenic soft agar assay includes all forms of cell death and the ability of single cells 
to proliferate i.e assesses the ability of cells to escape anoikis (detachment-induced cell 
death) and therefore survive to proliferate and form colonies 161.  To this end, we utilized 
clonogenic soft agar assay to assess the ability of PyMT-Luc cells to survive in an 
anchorage-independent condition as well as proliferate to form colonies under various 
conditions.  Conditioned media derived from wild type primary osteoblasts induced 
significantly higher metabolic activity of tumor cells and a statistical higher number of 
tumor colonies compared to tumor cells incubated with conditioned media from MMP-2 
deficient osteoblasts (Figure 20A).  However, no difference was observed in the average 
size of the colonies between the two conditions, suggesting that the absence of MMP-2 in 
osteoblasts affects tumor survival but not tumor growth which is in agreement with our in 
vivo data (Figure 20B).  To confirm that osteoblast-derived MMP-2 mediates this 
phenomenon, recombinant MMP-2 was added to conditioned media from MMP-2 
deficient primary osteoblasts prior to treatment of PyMT-Luc cells.  Addition of 
exogenous MMP-2 to conditioned media from MMP-2 deficient osteoblasts rescued 
metabolic tumor cell activity (Figure 20E and F).  These in vitro assays demonstrated for 
the first time that osteoblast-derived MMP-2 contributes to tumor survival. 
 Next we examined the molecular mechanism through which osteoblast-derived 
MMP-2 mediated the tumor survival effect.  MMP-2 can process numerous growth and 
survival factors in particular TGF-β whose role in modulating the vicious cycle, including 
osteoblast and osteoclast differentiation and function, has been well described 85, 98, 134. 
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TGF-β is maintained in a latent form via its complex with the latency associated peptide 
(LAP) and the latent TGF-β binding protein (LTBP-1-4).  Successive proteolytic 
cleavages induce the release of the active growth factor 162, 163. LTBP-3 deficient mice 
displayed a distinct cranial phenotype and develop osteopetrosis, therefore suggesting its 
key role in controlling the bioavailability of TGF-β in the bone 164, 165. Furthermore, 
LTBP-3 has been shown to be important for osteogenic differentiation of human 
mesenchymal stem cells 166. Therefore, we tested the hypothesis that LTBP-3 is a 
substrate of MMP-2, and osteoblast-derived MMP-2 induces the release of TGF-β which 
influences the mammary tumor survival. To assess the susceptibility of LTBP-3 for 
proteolytic processing, the conditioned medium of COS-7 cells overexpressing the large 
latent complex of LTBP-3 and LAP-TGF-β was subjected to digestion with recombinant 
active MMP-2. The molecular weight of the complex was reduced from ~240 kDa to 
~230-220 kDa in presence of recombinant active MMP-2, a processing event that has 
been previously reported to produced a ~ 230 kDa fragment consistent with that of 
plasmin (Figure 20C) 167. These data suggest that MMP-2 has the ability to process the 
latency binding protein that sequesters TGF-β in the bone matrix. 
 Since our results demonstrate that MMP-2 can process LTBP-3, we then tested 
the hypothesis that active TGF-β could mediate the survival of PyMT –Luc cells using a 
clonogenic soft agar assay.  Treatment of the tumor cells with TGF-β significantly 
increased the number of colonies but not the size of the colonies compared to control 
conditions (Figure 20D). Next, to assess the possibility that TGF-β could influence 
metabolic tumor cell activity in conditioned media from osteoblasts, neutralizing TGF-β 
antibody, 2G7, was used to treat cell culture media harvested from wild type and MMP-2 
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deficient primary osteoblasts.  Blocking of TGF-β in conditioned media of wild type 
osteoblasts significantly reduced tumor metabolic activity in an MTT assay (Figure 20E 
and F).  These data indicate that osteoblast-derived MMP-2 can control the levels of 
active TGF-β in the tumor-bone microenvironment and thus influence tumor growth. 
 
Osteoblast-derived MMP-2 contributes to the levels of active TGF-β in the bone 
microenvironment in vivo 
Next, we evaluated the levels of latent TGF-β in vivo by immunoblotting tissue lysates 
derived from the tumor bearing limbs of wild type and MMP-2 deficient mice 3 days 
post-injection for the LAP-TGF-β complex.  Samples of MMP-2 deficient tibias injected 
with tumor showed a significantly higher level of inactive LAP-TGF-β compared to the 
controls (Figure 21A). To investigate whether higher levels of TGF-β impacted the 
tumor-bone microenvironment, the status of TGF-β signaling was assessed by 
immunoblotting for phospho Smad2, the main intracellular effector of TGF-β receptor 
II/TGF-β signaling pathway 168. Lysates of tumor bearing tibias from MMP-2 deficient 
mice displayed a significant lower ratio of phospho smad2 over total smad2 compared to 
wild type controls (Figure 21B).  Taken together, these data show for the first time that an 
osteoblast-derived MMP, MMP-2, contributes to tumor survival in the tumor-bone 
microenvironment by controlling the activation of TGF-β. 
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Conclusions 
Despite the improvement in diagnosis and treatment, human breast-to-bone metastases 
remain incurable.  Therefore, a better understanding of the mechanisms underlying how 
tumor cells induce the vicious cycle remains a priority in order to develop new therapies 
that will treat/cure the disease. This study demonstrated for the first time that osteoblast-
derived MMP-2 contributes to the survival of two mammary tumor cell lines (PyMT-Luc 
and 17L3C-Luc) in the bone microenvironment and contributes to tumor-induced 
osteolysis in immunocompetent animals.  Furthermore, our results showed that 
osteoblast-derived MMP-2 promotes tumor survival but not tumor proliferation via a 
TGF-β dependent mechanism that potentially induces the processing of a novel MMP-2 
substrate, LTBP-3 (Figure 22).  Our studies suggest that therapies geared towards 
selectively inhibiting MMP-2 may be of clinical use for the treatment of breast-to-bone 
metastasis. 
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CHAPTER V 
 
DISCUSSION, FUTURE DIRECTIONS AND CONCLUSIONS 
 
Breast to bone metastasis is an incurable disease which affects more than 70 % of 
patients presenting with advanced breast cancer 5.  Lytic bone lesions cause severe 
complications that greatly affect the quality of life of the patients 6.  Currently, no cure 
can be offered to patients suffering with bone metastasis, only palliative treatments such 
as bisphosphonates, surgery, radiotherapy and chemotherapy are available.  Therefore, 
finding new molecular mechanisms underlying cell-cell communication in the tumor-
bone microenvironment is key for the development of better therapies.  Although human 
clinical trials using broad spectrum MMPIs were disappointing in the treatment of cancer, 
numerous pre-clinical studies demonstrated the potential efficacy of inhibiting MMPs in 
the context of bone metastasis 135, 137-139, 141.  As a result, bone metastasis appears to be a 
relevant target for the use of MMPIs; however, the specific role of individual MMPs in 
the lytic tumor-bone microenvironment must be elucidated so that highly selective 
MMPIs that lack the side effects noted with broad spectrum inhibitors can be generated 
140.  
The aims of this dissertation were to understand the contributions of host-derived 
MMPs to mammary tumor growth and mammary tumor-induced osteolysis in the bone 
microenvironment.  Immunostaining for different MMPs in human breast-to-bone 
metastasis samples showed MMP-7 and MMP-9 expression primarily within the mature 
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osteoclasts present at the tumor-bone interface.  However, MMP-2 staining was detected 
in the tumor and host cells such as osteoblasts and osteocytes.  Since these three host cell 
types (osteoclasts, osteoblasts and osteocytes) are the main effectors of the bone 
remodeling process, we tested the effect of host MMP-2, -7 and -9 ablation in a mouse 
model of mammary tumor growth and tumor-induced osteolysis using intratibial injection 
in MMP deficient animals.  Our studies established that osteoclast-derived MMP-7 and 
osteoblast-derived MMP-2 contribute to the vicious cycle through two distinct molecular 
mechanisms.  We demonstrated that osteoclast-derived MMP-7 enhances bone resorption 
via the solubilization of RANKL and that osteoblast-derived MMP-2 promotes tumor 
survival in the bone by processing TGF-β latency proteins such as LTBP-3, thereby 
controlling the levels of active TGF-β.  Interestingly, osteoclast-derived MMP-9 does not 
impact tumor growth and bone resorption in our mouse model.  These data demonstrated 
that although different host MMPs are expressed by mature osteoclasts, they do not all 
impact bone resorption in a tumor setting.  Additionally, our studies showed that MMPs 
expressed by distinct cell types can contribute differently to tumor growth and bone 
resorption by multiple molecular mechanisms. 
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Discussion 
 
Osteoclast-derived MMP-7 contributes to tumor growth-induced bone lesions via the 
solubilization of RANKL 
The results presented in this dissertation show an osteoclast derived protease, MMP-7, 
can promote osteoclast activation in the tumor-bone microenvironment by generating an 
active soluble form of the osteoclastogenic factor, RANKL and suggest that selective 
inhibition of MMP-7 may be of benefit for the treatment of lytic metastases.  Our study 
demonstrate that MMP-7 deficient mice bearing tumor have significantly lower levels of 
soluble RANKL and statistically reduced bone resorption, therefore suggesting that 
MMP-7 solubilization of RANKL mediates tumor-induced osteolysis (Figures 11, 12 and 
13).  However, in tumor bearing MMP-7 deficient mice bone resorption, although 
significantly attenuated, still occurs, thus MMP-7 may contribute to tumor growth-
induced bone lesions via other mechanisms.  For example, MMP-7 has been shown to 
process other members of the TNF family beside RANKL such as Fas ligand (FasL) and 
TNF-α 72, 169.  Fas/FasL are apoptotic factors and the solublization of FasL by MMP-7 
may directly impact tumor survival 148.  Furthermore, Kovacić and coworkers 
demonstrated the importance of Fas/Fas ligand in osteoblast differentiation by inhibiting 
progenitor differentiation and therefore, MMP-7 could indirectly affect 
osteoclastogenesis by impairing osteoblast functions through the processing of FasL 170.  
TNF-α has been demonstrated to be important for the final step of osteoclastogenesis i.e. 
the fusion of tartrate-resistance acid phosphatase-positive mononuclear osteoclasts 171.  
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Release of soluble active TNF-α by MMP-7 may directly promote activation of mature 
osteoclasts and lead to osteolysis.  Therefore, through the processing of different 
members of the TNF family such as TNF-α, FasL and RANKL, MMP-7 can impact 
osteoblast and osteoclast biology and ultimately bone resorption. 
The direct processing of the bone matrix by MMP-7 may be a possibility.  
Acidification and cathepsin-K secretion into osteoclast resorption lacunae allows for the 
demineralization and collagenolysis of the bone matrix respectively 77.  Therefore, the 
direct resorption of the bone matrix by MMP-7, functional at a more neutral pH, is highly 
unlikely.  However, by a process known as transcytosis, the osteoclast mediates the 
removal of bone products from the area of bone undergoing resorption 172. Given the 
punctuate localization of MMP-7 by immunofluorescent staining it is tempting to 
speculate that MMP-7 contributes to the further processing of bone matrix components 
such as osteopontin 66, or the release of growth factors from bone matrix components 
such as TGF-β and IGFs, within these transcytotic vesicles 57 173 
Since MMP-7 deficient mice used in this study lack the metalloproteinase in the 
entire stromal compartment, the expression of MMP-7 by other cellular sources may also 
be a possibility.  However, in the tumor-bone microenvironment, we observed that MMP-
7 expression was largely confined to osteoclasts (Figures 5 and 8).  Nevertheless MMP-7 
has also been shown to be expressed by macrophages and given the role of macrophages 
in tumor induced osteolysis, the contribution of macrophage derived MMP-7 in our 
model or in humans cannot be discounted 174, 175.   
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Given the role of MMP-7 in osteoclast function in the pathological setting of 
tumor induced osteolysis, it is surprising that MMP-7 null animals appear to have a 
normal skeletal phenotype.  Data presented here using µCT scan analysis demonstrate a 
similar BV/TV ratio between MMP-7 null and wild type control mice at 6 weeks of age 
(Figure 8).  While a role for MMP-7 in bone development has not been explored, a 
number of reports have revealed that the phenotype of the MMP-7 null animals is often 
only apparent in response to injury/challenges or disease.  For example, in non-
pathological conditions such as herniated disc resorption, macrophage derived MMP-7 is 
critical for the resorption of the herniated disc 72.  In mammary and prostate involution, 
MMP-7 processing of FasL is important for initiating apoptosis 72, 148, 176.  More often, 
phenotypes in the MMP-7 null animals have been observed in pathological conditions 
such as pancreatitis, colon tumorigenesis, mammary gland tumorigenesis and in innate 
defense wherein MMP-7 null animals show significant delays in disease progression or in 
response to infection 177-180.  Therefore, although MMP-7 null mice lack an apparent 
skeletal phenotype, in the context of tumor-bone microenvironment, it is clear based on 
the results of our study that host MMP-7 plays an important role in the mammary tumor-
bone microenvironment.  In addition, our observations defining a role for MMP-7 in bone 
diseases are consistent with previous reports that implicate roles for host MMP-7 in 
prostate cancer induced osteolysis, osteoarthritis and cartilage/periarticular bone 
destruction 71, 116, 181.    
Finally, our data demonstrate that osteoclast-derived MMP-7 affects mammary 
tumor growth in the bone by enhancing tumor survival (Figure 9).  Our results show that 
in the MMP-7 deficient animals, a failure to generate active soluble RANKL leads to a 
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decrease in the number of mature bone resorbing osteoclasts that in turn leads to a 
decrease in tumor growth by depriving the tumor cells of survival factors such as TGF-β, 
or IGF.  In this regard, the levels of active TGF-β in tissue lysates from wild type or 
MMP-7 deficient mice bearing tumor were assessed by ELISA and no significant 
difference were observed between the two groups of animals (Figure 23).  Therefore, host 
MMP-7 impacts tumor survival by an as yet unidentified factor(s) such as IGFs. 
 
Osteoclast-derived MMP-9 does not contribute to mammary tumor growth-induced bone 
resorption 
Although MMP-9 was localized to human and murine osteoclasts, the ablation of host 
MMP-9 did not appear to impact PyMT-Luc tumor growth and bone resorption compared 
to the wild-type controls.  Analogous results were obtained by Nabha et al., using the 
same intratibial model but in the context of prostate cancer progression in the bone 147.  
Given the importance of MMP-9 in osteoclast migration and recruitment in developing 
long bones, these results were surprising 75. It appears that in the tumor-bone 
microenvironment, MMP-9 is not critical for osteoclast function.  The possibility that 
tumor-derived MMP-9 could overcome the absence of host MMP-9 exists in our model, 
however, in vivo studies conducted in the Matrisian laboratory have demonstrated that 
MMP-9 expression by the PyMT-Luc tumor cells is not detectable 146.  Therefore, the 
ability of tumor derived MMP-9 to circumvent the loss of host derived MMP-9 and 
impact tumor progression in the bone is unlikely.  In comparison, the dramatic effect on 
tumor growth and bone resorption observed in MMP-2 deficient mice upon tumor  
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injection was surprising since MMP-2 and MMP-9 are closely related in structure.  Our 
studies in the mammary tumor-bone microenvironment suggest that despite their 
similarities in terms of structure and substrates, MMP-2 and MMP-9 are 1) expressed by 
different cell types and 2) have very distinct functions with respect to the progression of 
the osteolytic vicious cycle.  In addition, these data reinforce the importance of assessing 
the contributions of individual MMPs to tumor progression in the bone in a bid to design 
selective MMPIs that lack the deleterious side effects noticed with broad spectrum 
inhibitors during human clinical trials.  
While our data points towards MMP-9 as not being critical for mammary tumor 
growth or induced osteolysis, it is important to note that MMP-9 could contribute to other 
steps of metastasis that are not taken into account with the intratibial model.  These 
include extravasation from the sinusoidal vasculature in the bone and initial survival, the 
latter of which has been shown to be an important role for host derived MMP-9 in early 
lung metastasis 182.  Furthermore, MMP-9 has been implicated in tumor angiogenesis by 
mediating the release of matrix sequestered vascular endothelial growth factor (VEGF) 76. 
In the context of the prostate tumor-bone microenvironment, Nabha and colleagues 
demonstrated a decrease in angiogenesis in MMP-9 null animals compared to wild type 
controls 147.  Therefore, the selective inhibition of MMP-9 may still prove useful in 
preventing the establishment and angiogenesis of bone metastases.  Studies have 
demonstrated the importance of MMP-9 in the formation of ‘pre-metastatic niches’ in a 
lung and skin metastasis murine models 76, 183-185.  Hiratsuka and coworkers showed that 
MMP-9 expression by endothelial cells and macrophages was induced in the lungs by 
distant tumors prior to metastasis 185.  Given the richness in immune cells and the highly 
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vascularized state of bone, it would be interesting to investigate the potential contribution 
of host MMP-9 to the establishment of bone metastastic niches in breast cancer 
progression.   
 
Osteoblast-derived MMP-2 impacts mammary tumor growth-induced bone lesions 
Our results demonstrate that osteoblast-derived MMP-2 affects mammary tumor survival 
in the bone.  It is of interest to note that mammary tumor virus (MMTV) long terminal 
repeat-polyoma middle-T antigen (MMTV-PyMT) mice deficient for MMP-2 do not 
show any difference in terms of mammary tumor incidence, onset, growth rate and tumor 
volume compared to wild type control mice, demonstrating that the effect of host MMP-2 
are specific to the bone microenvironment (Fingleton and Matrisian, personal 
communication). 
   Our study suggests that osteoblast-derived MMP-2 can modulate the release of 
TGF-β via the processing of LTBP-3 (Figure 20).  TGF-β is sequestered in a latency 
complex comprised of LTBP-1-4 and LAP and that these complexes must be sequentially 
processed in order to generate active TGF-β 120-124.  The binding of LAP-TGF-β to LTBP 
is thought to be important for the binding of latent TGF-β to the ECM.  The processing of 
LTBP releases LAP-TGF-β from the ECM which can be activated by further proteolytic 
processing 186, 187.  Other members of the LTBP family such as LTBP-1 have been shown 
to be substrates for MMPs, in particular MMP-2 124, 188, 189.  In addition, a recent study 
using a multiplex proteomics approach, identified LTBP-4 as a potential novel substrate 
for MMP-2 190. However, of the four members of the LTBP family, only LTBP-3 
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deficient mice are reported as having skeletal defects including osteoarthritis and 
osteopetrosis 164, 165.  MMP-2 has also been shown to process LAP-TGF-β leading to the 
release of the active form of the growth factor 188.  Our study identifies for the first time 
that osteoblast-derived MMP-2 is responsible for the cleavage of LTBP-3 and we posit 
that based on other studies that MMP-2 subsequently cleaves LAP-TGF-β to release 
active TGF-β 122.  This conclusion is supported by our observations (Figures 20 and 21).  
While we suggest that MMP-2 is critical for TGF-β activation, the role of other proteases 
that can process TGF-β latency complexes such as plasmin and MMP-9 may also 
contribute and explain why residual levels of active TGF-β could be identified in the 
conditioned media of MMP-2 deficient osteoblasts (Figures 20 and 21) 122, 191.     
Our results suggest that MMP-2-mediated activation of TGF-β is the primary 
mechanism responsible for tumor survival in the bone (Figure 20).  However, MMP-2 
could impact tumor survival through the processing of other bone factors 98.  IGFs are 
sequestered in a latent complex through their interactions with IGF binding proteins 
(IGFBP-1 to -4) 125 and several MMPs, including MMP-2 have been shown to process 
different members of the IGFBP family resulting in the activation of IGFs 131, 192, 193.  
However, we determined active IGF signaling levels in tissue lysates of tumor bearing 
limbs from wild type and MMP-2 deficient mice by immunoblotting for phospho IGF-
receptor 1 (IGF-1R). No difference between MMP-2 deficient and wild type control 
animals was observed in terms of the phosphorylation levels of IGF-1R (data not shown). 
These data further support our conclusion that MMP-2 activation of TGF-β is a major 
mechanism mediating tumor survival in the tumor-bone microenvironment.  However, 
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we acknowledge that other reported substrates of MMP-2 may also contribute to tumor 
survival (see table 2 in chapter I). 
 A potential molecular mechanism through which TGF-β can mediate its anti-
apoptotic effect is the activation of phosphatidylinositol-3 kinase (PI3K)/Akt pathway. 
By regulating Smad3 activation, Akt has been shown to protect liver cancer cells from 
apoptotsis 194, 195.  Furthermore, Muraoka-Cook and colleagues demonstrated that TGF-β 
can signal to PI3K/Akt signaling pathway to enhance mammary tumor survival 196.  In 
addition, TGF-β has been shown to induce NF-ĸB activity and promote cell survival.  
Treatment of activated hepatic stellate cells with TGF-β induced the activation of NF-ĸB 
and suppressed apoptosis 197.  Therefore activation of PI3K/Akt or NF-ĸB pathways in 
mammary tumor cells by osteoblast-derived TGF-β could potentially mediate tumor 
survival in our mouse model.  
 The majority of the studies examining the osteolytic vicious cycle conducted so 
far have focused almost exclusively on the ‘forward’ communication i.e. tumor cell 
control of osteoblast behavior that in turn impacts osteoclastic bone resorption (Figure 
24).  For the first time, our study demonstrates the in vivo ‘reverse’ communication i.e. 
osteoblast control of tumor cells behavior in the vicious cycle. For instance, in the 
‘forward setting’, tumor-derived factors such as parathyroid hormone-related peptide 
(PTHrP) have been extensively studied as its expression by metastatic breast tumor cells 
induces osteoclastic bone resorption via osteoblast-dependent activation of osteoclast 
precursors 95, 112, 198.  In addition, osteoclast-mediated bone resorption releases TGF-β that 
in turn affects PTHrP expression by tumor cells 87, 112, 199.  However, the ‘reverse setting’  
89 
 
 90 
 
i.e. the direct modulation of the tumor cell behavior by osteoblasts and the molecular 
mechanisms therein, have thus far not been assessed.  Our results are the first to 
demonstrate the importance of osteoblast-derived signals in controlling tumor survival 
(Figures 17 and 20).    
Besides its effects on tumor growth, TGF-β has been shown to modulate both 
osteoblast and osteoclast functions 200-204. Therefore, MMP-2-mediated release of active 
TGF-β may also directly affect osteoblast-osteoclast interactions. Our studies revealed a 
decrease in tumor-induced osteolysis (Figure 18).  While our observations ruled out a 
direct role for MMP-2 in osteoclast maturation and activation, we speculate that 
osteoblast-derived MMP-2 impacts osteoclastogenesis via the processing of LTBP-3 and 
activation of TGF-β (Figures 19 and 20).  TGF-β has been shown be sufficient to induce 
osteoclastogenesis but also to support and/or increase osteoclast activation 205 206, 207.  
Therefore, it is possible that the release of TGF-β by osteoblast-derived MMP-2 induces 
an increase in osteoclastogenesis in addition to its effects on tumor survival.  
Furthermore, a recent study demonstrated that treatment of mature mice with TGF-β type 
I receptor kinase inhibitor, SD-208, induces increase bone mineral density, bone mass 
and mineral concentrations indicating an effect on osteoblast functions 208.  Mice treated 
with SD-208 had significantly higher number of osteoblasts and significantly reduced 
number of osteoclasts 208.  Although, we observed a significant decreased in trabecular 
bone volume in tumor bearing limbs, we acknowledge that an autocrine effect of 
osteoblast-derived TGF-β could occur in our mouse model. 
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 Our study demonstrates that MMP-2 secreted by osteoblasts impacts mammary 
tumor growth and mammary tumor-induced osteolysis.  However, since MMP-2 is 
entirely eliminated in the MMP-2 deficient animals, we cannot rule out that MMP-2 
derived from other cell types is of importance in mediating tumor survival and bone 
resorption.  For example, immune cells have been shown to express MMPs, including 
MMP-2 and recent findings demonstrated that T cells (a rich source of MMP-2) modulate 
tumor-induced bone resorption 209, 210.  Thus, a contribution of MMP-2 secreted by 
immune cells such as T cells that are present in our syngeneic immunocompetent mice 
cannot be disregarded.  Inoue and coworkers reported the importance of MMP-2 in 
maintaining proper osteocytic canicular network caused by a defect in osteocyte 
functions and increased apoptosis 68.  Osteocytes are important in controlling bone mass 
through the modulation of osteoblast/osteoclast function via the secretion of factors such 
as sclerostin 15, 16.  As a consequence, we acknowledge that reduced osteolysis in a tumor 
setting could be caused by osteocyte function to regulate bone remodeling is a possibility 
in our model but that has not been explored thus far. 
Although, MMP-2 does not directly affect osteoclast maturation and activation, its 
contribution to direct bone resorption may exist.  MMP-2 has collagenase activity and 
hence osteoblast-derived MMP-2 could directly contribute to bone resorption after the 
exit of the osteoclasts 61.  This degradation of the bone can generate ICTP fragments of 
type I collagen that in turn can promote further osteoclast precursor cell recruitment 60, 62-
64.  While host MMP-2 can potentially work through these suggested mechanisms in our 
model, our data clearly identifies a role for osteoblast-derived MMP-2 given our results 
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with treatment of tumor cells with conditioned media derived from osteoblasts in vitro  
and our observation in vivo (Figures 20 and 21). 
 
Is there a place for selective MMP-2 and MMP-7 inhibitors in treatment of breast-to-
bone metastases? 
Breast-to-bone metastases are incurable and with the exception of surgery and radiation, 
bisphosphonates are the most common approach to treat patients.  Despite the success of 
bisphosphonates, their use is often palliative 211.  Bisphosphonates are classified as non-
nitrogen-containing bisphosphonates or nitrogen-containing bisphosphonates (NBPs), 
according to their chemical structure 212.  NBPs such as pamidronate, ibandronate, 
risedronate and zoledronic acid have a better anti-resorptive effect than the non-nitrogen-
containing bisphosphonates.  NBPs prevent bone resorption through the inhibition of 
osteoclast activity and the induction of osteoclast apoptosis 213, 214.  Despite their proven 
efficacy in treating breast cancer-associated bone lesions, bisphosphonates are not an 
ideal long-term therapy since they present minimal effect on survival and they have 
minimal oral bioavailability and a long half-life which increases the risk to develop 
osteonecrosis of the jaw 215, 216.  Therefore, there is still a growing interest in developing 
new therapeutic agents targeting key components of the ‘vicious cycle’. 
Pre-clinical studies in animal models of tumor bone metastasis have demonstrated 
that the use of MMPIs remains a relevant approach to treat lytic bone lesions 137-139.  
Treatment of tumor bearing animals with broad spectrum MMPIs such as BB-94 have 
been shown to prevent bone resorption induced by prostate and breast tumor cells 137, 138.  
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Weber and co-workers showed that the use of Neovastat, a reagent with reported 
metalloproteinase inhibition ability, can prevent the development of lytic lesions during 
tumor growth in the bone 217.  Furthermore, the combined effects of a bisphosphonate 
(ibandronate) and TIMP-2 in a mouse model of mammary tumor-induced osteolysis 
showed a decrease in bone resorption and an increased survival rate 218.  Taken together, 
these data demonstrate the potential efficacy of using MMP inhibitors in treating bone 
lesions during cancer progression.  However, a better understanding of the specific roles 
of individual MMPs to the bone metastasis process is required to avoid musculoskeletal 
side effects observed during the first clinical trials with broad spectrum inhibitors 135.  In 
this regard, a recent study reported that SB-3CT, an MMP-2 and MMP-9 selective 
inhibitor was effective in controlling prostate tumor growth and osteolysis 141.  However, 
prinomastat, a selective MMP-2 and MMP-9 inhibitor, has been shown to cause 
musculoskeletal side effects 219.  Based on our results, a generation of reagents with 
further specificity against MMP-2 but not MMP-9 may provide efficacy without side 
effects.  Our studies also suggest that the selective inhibition of MMP-7 would be 
effective in halting the vicious cycle.  Regardless of the efficacy of the MMP inhibitors, 
identifying the molecular mechanisms through which individual MMPs mediate their 
effect can also result in the generation of new therapies, for example LTBP-3 and 
RANKL that ultimately will be of benefit to patients with lytic bone metastases. 
 
 
 
94 
 
Future directions 
Our studies show mature osteoclasts as a rich source of MMP-7.  However, to rule out 
any effects of MMP-7 on mammary tumor growth and bone resorption from other 
cellular sources, the generation of a mouse specifically deficient for MMP-7 in 
osteoclasts would be important.  Therefore, a specific osteoclast MMP-7 deficient mouse 
using a Cre/LoxP flanked MMP-7 construct approach could be engineered.  These 
specific MMP-7 deficient mice will allow us to investigate the precise contribution of 
osteoclast-derived MMP-7 in tumor growth and tumor-induced osteolysis. 
We demonstrate in this dissertation that osteoclast-derived MMP-7 affects tumor-
induced osteolysis via the solublization of RANKL.  The use of a specific transgenic 
mouse expressing membrane-bound RANKL resistant to proteolytic processing would 
allow for the assessment of the importance of soluble RANKL versus full length RANKL 
to mammary tumor growth-induced osteolysis.  Since the sequence of the RANKL 
cleavage site by MMP-7 has previously been reported, using site directed mutagenesis, an 
MMP-7-resistant RANKL could be engineered 116.  First, an MMP-7-resistant RANKL 
osteoblast cell line could be established and in vitro the functionality of this osteoblastic 
cell line in terms of ability to induce osteoclast activation could be assessed.  Finally, 
using a systemic knock in MMP-7-reistant RANKL mouse would allow for the 
assessment of the effect of this protein on the development of the skeleton and in the 
context of mammary tumor growth in the bone.  
Our study showed that osteoclast-derived MMP-9 does not impact tumor growth 
in the bone.  Therefore, the use of intracardiac injection as a model of breast to bone 
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metastasis would allow us to assess the potential contributions of host-derived MMP-9 in 
early steps to metastasis.  Since MMP-9 has been shown to be important for the 
establishment of a ‘pre-metastatic niche’ in experimental lung and skin cancer metastasis 
models, it would be of interest to investigate the potential contribution of host MMP-9 in 
the formation of a ‘bone metastatic niche’ 76, 183-185.  Orthotopic injection of mammary 
tumor cells and examination of the bone for ‘pre-metastatic’ markers such as VEGFR1 or 
fibronectin would assess this interesting question. 
Our work in MMP-2 deficient mice demonstrates that MMP-2 secreted by 
osteoblasts impacts tumor survival in the bone.  However, we cannot rule out that MMP-
2 derived from other sources is of importance, therefore future studies could directly 
assess the importance of osteoblast-derived MMP-2 without disturbing other host cell 
type functions.  Using inducible MMP-2 deficient animals such as an MMP-2/Tet 
transgenic mice where the Tet transactivator is under the control of a collagen type I α1 
promoter to allow for specific osteoblast expression.  Furthermore, in this dissertation, we 
posit that MMP-2 controls the release of active TGF-β via LTBP-3 processing.  Future 
studies could identify the cleavage site for MMP-2 on LTBP-3 to generate an MMP-2 
resistance LTBP-3 by site directed mutagenesis and establish an MMP-2 resistance 
LTBP-3 osteoblast cell line.  First, the in vitro functionality of the MMP-2-resistant 
LTBP-3 osteoblast cell line in terms of proliferation, differentiation and induction of 
osteoclast activation and expression levels could be assessed.  The importance of LTBP-3 
cleavage by MMP-2 to mammary tumor survival in the bone in vivo could be analyzed 
using a knock in MMP-2 resistant mouse.  
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Finally, with respect to the importance of osteoblast-derived MMP-2 in tumor 
growth in the bone, it would be interesting to investigate the effect of host MMP-2 
ablation in a model of prostate to bone metastasis.  Once in the bone, prostate tumor cells 
induce mixed lesions containing excess of osteoblastic and osteolytic response 220.  To 
this end, a model of murine prostate cancer in the bone developed by Lynch and 
colleagues where prostate adenocarcinoma samples are transplanted into the cranial 
region of immunocompromised MMP-2 deficient mice (RAG-2 deficient mice) would 
permit the assessment of MMP-2 function in a tumor-induced osteoblastic setting 116. 
 
Conclusions 
The results of my thesis demonstrated: 
• Mature osteoclasts at the tumor-bone interface are a rich source of MMP-7 
and MMP-9. 
• Osteoclast-derived MMP-7 impacts mammary tumor growth and tumor 
induced osteolysis. (First time observation) 
o Molecular mechanism: solublization of membrane-bound RANKL 
by MMP-7 that mediates maturation/activation of osteoclast 
precursor cells. 
• Osteoclast-derived MMP-9 does not contribute to either mammary tumor 
growth or bone resorption. 
• Osteoblasts are a rich source of MMP-2. 
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• Osteoblast-derived MMP-2 impacts mammary tumor growth by enhancing 
tumor survival. (First report to show this) 
• Host-MMP-2 impacts mammary tumor-induced osteolysis. (First report) 
• MMP-2 can modulate the release of active TGF-β via the processing of its 
latency protein, LTBP-3. (First report) 
• Osteoblast-derived MMP-2 and osteoblast-derived TGF-β mediate 
mammary tumor survival. (First report) 
In conclusion, this dissertation demonstrates that osteoblast-derived MMP-2 controls the 
levels of active TGF-β via the processing of LTBP-3 and thereby mediates tumor survival 
in the tumor-bone microenvironment.  In addition, our results showed that osteoclast-
derived MMP-7 but not MMP-9 mediates mammary tumor-induced osteolysis through 
RANKL solublization (Figure 25).  Therefore, novel therapeutic agents focusing on 
major components of the ‘vicious cycle’ will improve the current treatment options 
offered to breast cancer patients with lytic bone metastases.  Development of specific 
MMP-2 and MMP-7 inhibitors or therapies that target their substrates would benefit 
patients whose response to bisphosphonates and other traditional treatment strategies are 
unsatisfactory.  Alternatively, these new therapeutic agents may also be useful as 
adjuvants in combination with bisphosphonates, denosumab (specific RANKL antibody), 
hormonal therapies or other treatments offered, to hopefully lead to the eradication of 
breast-to-bone metastasis. 
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